title: Whole blood, SLE patient 9 Dose 1 on Week 0, placebo

description:
AP511436A29
A2786_2574

source_name: SLE Patient 9 Dose 1 on Week 0


title: Whole blood, SLE patient 9 Follow-up on Week 36, placebo

status: Public on Oct 08 2021

type: RNA

city: Brussels

first: Frédéric

middle: A

last: HOUSSIAU

address: Avenue Hippocrate 10

department: Institut de recherche expérimentale et clinique (IREC)

country: Belgium

institute: Université catholique de Louvain

description:
AP061079B30
A2786_2577

hyb_protocol: Following fragmentation and biotin labeling, 4.4 µg of cDNA were hybridized for 16 hours at 45C on GeneChip Human Genome U133 Plus 2.0 array. GeneChips were washed and stained in the Affymetrix GeneChip Fluidics Station 450.

scan_protocol: GeneChips were scanned using the Affymetrix Gene Chip Scanner 3000.

data_processing: The data were analyzed and RMA normalized using the Affymetrix Expression Console software v.1.4.1.

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: SLE Patient 9 Follow-up on Week 36

label_protocol: 100 ng total RNA was labeled using the NuGen WB Solution kit according to the manufacturer's instructions.

extract_protocol: Total RNA was extracted from PAXgene blood RNA tubes using the QIASymphony SP extraction robot from QIAGEN. The QIASymphony PAXgene blood RNA Extraction kit and PAXgene_RNA protocol were used.

treatment_protocol: Patients with SLE (185) with moderate to severe disease activity and positive interferon (IFN) gene signature were randomised to receive IFN-K or PBO intramuscular injections (on W0, W1, W4 and W12 and W24). At randomisation (D0) and W12, W24 and W36, the IFN gene signature, including the 21 IFN-regulated genes, was evaluated by Affymetrix.

tag: diagnosis

value: SLE

tag: treatment

value: PBO

tag: time point

value: Follow-up on Week 36

tag: tissue

value: Blood

tag: patient

value: Patient 9


title: Whole blood, SLE patient 4 Dose 4 on Week 12, placebo

description:
AP020570B28
A2786_2579

source_name: SLE Patient 4 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 4


title: Whole blood, SLE patient 4 Dose 1 on Week 0, placebo

description:
AP417219A07
A2786_2578

source_name: SLE Patient 4 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE patient 9 Dose 5 on Week 24, placebo

description:
AP061074B29
A2786_2576

source_name: SLE Patient 9 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 106 Dose 5 on Week 24 ; IFN-K

description:
EP871836A29
A2786_2572

source_name: SLE Patient 106 Dose 5 on Week 24

value: IFN-K

value: Patient 106


title: Whole blood, SLE Patient 106 Follow-up on Week 36 ; IFN-K

description:
EP048794B08
A2786_2573

source_name: SLE Patient 106 Follow-up on Week 36


title: Whole blood, SLE Patient 106 Dose 4 on Week 12; IFN-K

description:
EP503101A28
A2786_2571

source_name: SLE Patient 106 Dose 4 on Week 12


title: Whole blood, SLE Patient 119 Follow-up on Week 36 ; IFN-K

description:
AP118881B30
A2786_2559

source_name: SLE Patient 119 Follow-up on Week 36

value: Patient 119


title: Whole blood, SLE Patient 119 Dose 5 on Week 24 ; IFN-K

description:
AP118871B29
A2786_2558

source_name: SLE Patient 119 Dose 5 on Week 24


title: Whole blood, SLE Patient 149 Follow-up on Week 36 ; IFN-K

description:
EP918372A30
A2786_2563

source_name: SLE Patient 149 Follow-up on Week 36

value: Patient 149


title: Whole blood, SLE Patient 149 Dose 5 on Week 24 ; IFN-K

description:
EP918367A29
A2786_2562

source_name: SLE Patient 149 Dose 5 on Week 24


title: Whole blood, SLE Patient 149 Dose 1 on Week 0; IFN-K

description:
EP410846A29
A2786_2560

source_name: SLE Patient 149 Dose 1 on Week 0


title: Whole blood, SLE Patient 119 Dose 4 on Week 12 ; IFN-K

description:
AP699318A29
A2786_2557

source_name: SLE Patient 119 Dose 4 on Week 12


title: Whole blood, SLE patient 71 Dose 5 on Week 24, placebo

description:
AP017016B29
A2786_2554_rh

source_name: SLE Patient 71 Dose 5 on Week 24

value: Patient 71


title: Whole blood, SLE Patient 106 Dose 1 on Week 0; IFN-K

description:
EP503088A29
A2786_2564

source_name: SLE Patient 106 Dose 1 on Week 0


title: Whole blood, SLE Patient 119 Dose 1 on Week 0; IFN-K

description:
AP451370A29
A2786_2556

source_name: SLE Patient 119 Dose 1 on Week 0


title: Whole blood, SLE Patient 149 Dose 4 on Week 12 ; IFN-K

description:
EP410854A29
A2786_2561

source_name: SLE Patient 149 Dose 4 on Week 12


title: Whole blood, SLE patient 71 Follow-up on Week 36, placebo

description:
AP510863B08
A2786_2555

source_name: SLE Patient 71 Follow-up on Week 36


title: Whole blood, SLE patient 71 Dose 1 on Week 0, placebo

description:
AP286388A08
A2786_2552

source_name: SLE Patient 71 Dose 1 on Week 0


title: Whole blood, SLE patient 46 Dose 1 on Week 0, placebo

description:
SP107569A08
A2786_2540

source_name: SLE Patient 46 Dose 1 on Week 0

value: Patient 46


title: Whole blood, SLE Patient 158 Dose 5 on Week 24 ; IFN-K

description:
EP519906A08
A2786_2530

source_name: SLE Patient 158 Dose 5 on Week 24

value: Patient 158


title: Whole blood, SLE Patient 88 Follow-up on Week 36; IFN-K

description:
EP999165A29
A2786_2531

source_name: SLE Patient 88 Follow-up on Week 36

value: Patient 88


title: Whole blood, SLE patient 46 Dose 5 on Week 24, placebo

description:
SP221251A08
A2786_2537

source_name: SLE Patient 46 Dose 5 on Week 24

value: SLE


title: Whole blood, SLE patient 71 Dose 4 on Week 12, placebo

description:
AP814663A09
A2786_2553

source_name: SLE Patient 71 Dose 4 on Week 12

value: PBO


title: Whole blood, SLE patient 21 Dose 4 on Week 12, placebo

description:
EP385867A08
A2786_2527

source_name: SLE Patient 21 Dose 4 on Week 12

value: Patient 21


title: Whole blood, SLE Patient 135 Dose 4 on Week 12 ; IFN-K

description:
SP221090A08
A2786_2538

source_name: SLE Patient 135 Dose 4 on Week 12

value: Blood

value: Patient 135


title: Whole blood, SLE Patient 135 Dose 1 on Week 0; IFN-K

description:
SP054783A07
A2786_2534

source_name: SLE Patient 135 Dose 1 on Week 0


title: Whole blood, SLE Patient 165 Dose 5 on Week 24; IFN-K

description:
AP765631A28
A2786_2550

source_name: SLE Patient 165 Dose 5 on Week 24

value: Patient 165


title: Whole blood, SLE patient 46 Follow-up on Week 36, placebo

description:
SP439436A08
A2786_2539

source_name: SLE Patient 46 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 165 Dose 1 on Week 0; IFN-K

description:
AP188426A30
A2786_2548

source_name: SLE Patient 165 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 135 Dose 5 on Week 24 ; IFN-K

description:
SP220498A08
A2786_2535

source_name: SLE Patient 135 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 88 Dose 4 on Week 12; IFN-K

description:
EP442424A07
A2786_2526

source_name: SLE Patient 88 Dose 4 on Week 12

value: IFN-K

value: Dose 4 on Week 12


title: Whole blood, SLE patient 67 Dose 4 on Week 12, placebo

description:
EP519903A08
A2786_2523

source_name: SLE Patient 67 Dose 4 on Week 12

value: Patient 67


title: Whole blood, SLE Patient 135 Follow-up on Week 36 ; IFN-K

description:
SP439447A08
A2786_2536

source_name: SLE Patient 135 Follow-up on Week 36


title: Whole blood, SLE Patient 165 Dose 4 on Week 12; IFN-K

description:
AP564782A07
A2786_2549

source_name: SLE Patient 165 Dose 4 on Week 12


title: Whole blood, SLE patient 21 Dose 5 on Week 24, placebo

description:
EP385868A08
A2786_2529

source_name: SLE Patient 21 Dose 5 on Week 24


title: Whole blood, SLE Patient 170 Dose 4 on Week 12 ; IFN-K

description:
EP381785A08
A2786_2518

source_name: SLE Patient 170 Dose 4 on Week 12

value: Patient 170


title: Whole blood, SLE patient 21 Follow-up on Week 36, placebo

description:
EP564229A30
A2786_2532

source_name: SLE Patient 21 Follow-up on Week 36


title: Whole blood, SLE Patient 165 Follow-up on Week 36; IFN-K

description:
AP273362B29
A2786_2551

source_name: SLE Patient 165 Follow-up on Week 36


title: Whole blood, SLE patient 67 Dose 5 on Week 24, placebo

description:
EP519901A08
A2786_2528

source_name: SLE Patient 67 Dose 5 on Week 24


title: Whole blood, SLE Patient 88 Dose 1 on Week 0; IFN-K

description:
EP178177A07
A2786_2515

source_name: SLE Patient 88 Dose 1 on Week 0


title: Whole blood, SLE Patient 158 Dose 1 on Week 0; IFN-K

description:
EP076050A07
A2786_2513

source_name: SLE Patient 158 Dose 1 on Week 0


title: Whole blood, SLE patient 19 Dose 1 on Week 0, placebo

description:
EE613344-7
A2786_2512

source_name: SLE Patient 19 Dose 1 on Week 0

value: Patient 19


title: Whole blood, SLE Patient 96 Follow-up on Week 36 ; IFN-K

description:
AP111414B30
A2786_2506

source_name: SLE Patient 96 Follow-up on Week 36

value: Patient 96


title: Whole blood, SLE patient 78 Follow-up on Week 36, placebo

description:
EP792477A08
A2786_2521

source_name: SLE Patient 78 Follow-up on Week 36

value: Patient 78


title: Whole blood, SLE patient 67 Dose 1 on Week 0, placebo

description:
EP076049A29
A2786_2520

source_name: SLE Patient 67 Dose 1 on Week 0


title: Whole blood, SLE Patient 123 Follow-up on Week 36 ; IFN-K

description:
AP990288A30
A2786_2507

source_name: SLE Patient 123 Follow-up on Week 36

value: Patient 123


title: Whole blood, SLE patient 19 Dose 4 on Week 12, placebo

description:
EF157127-8
A2786_2522

source_name: SLE Patient 19 Dose 4 on Week 12

value: SLE


title: Whole blood, SLE patient 78 Dose 5 on Week 24, placebo

description:
EP370063A08
A2786_2508

source_name: SLE Patient 78 Dose 5 on Week 24

value: PBO


title: Whole blood, SLE Patient 170 Dose 5 on Week 24 ; IFN-K

description:
EP381779A08
A2786_2524

source_name: SLE Patient 170 Dose 5 on Week 24


title: Whole blood, SLE patient 78 Dose 1 on Week 0, placebo

description:
EP076743A07
A2786_2517

source_name: SLE Patient 78 Dose 1 on Week 0


title: Whole blood, SLE patient 78 Dose 4 on Week 12, placebo

description:
EP370059A08
A2786_2525

source_name: SLE Patient 78 Dose 4 on Week 12


title: Whole blood, SLE Patient 123 Dose 5 on Week 24 ; IFN-K

description:
AP990280A08
A2786_2501

source_name: SLE Patient 123 Dose 5 on Week 24


title: Whole blood, SLE Patient 158 Dose 4 on Week 12; IFN-K

description:
EP076048A07
A2786_2519

source_name: SLE Patient 158 Dose 4 on Week 12

value: Patient 158


title: Whole blood, SLE patient 8 Follow-up on Week 36, placebo

description:
AP061080B08
A2786_2499

source_name: SLE Patient 8 Follow-up on Week 36

value: Blood

value: Patient 8


title: Whole blood, SLE patient 21 Dose 1 on Week 0, placebo

description:
EP385861A29
A2786_2725

source_name: SLE Patient 21 Dose 1 on Week 0

value: Patient 21


title: Whole blood, SLE patient 8 Dose 5 on Week 24, placebo

description:
AP061073B08
A2786_2504

source_name: SLE Patient 8 Dose 5 on Week 24


title: Whole blood, SLE Patient 170 Follow-up on Week 36 ; IFN-K

description:
EP664469A08
A2786_2509

source_name: SLE Patient 170 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 109 Follow-up on Week 36; IFN-K

description:
AP134050B07
A2786_2502

source_name: SLE Patient 109 Follow-up on Week 36

value: Patient 109


title: Whole blood, SLE Patient 170 Dose 1 on Week 0; IFN-K

description:
EP075558A07
A2786_2510

source_name: SLE Patient 170 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 109 Dose 5 on Week 24; IFN-K

description:
AP134042B07
A2786_2500

source_name: SLE Patient 109 Dose 5 on Week 24

value: IFN-K

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 96 Dose 5 on Week 24 ; IFN-K

description:
AP620476A08
A2786_2496

source_name: SLE Patient 96 Dose 5 on Week 24


title: Whole blood, SLE patient 8 Dose 1 on Week 0, placebo

description:
AP143604A29
A2786_2497

source_name: SLE Patient 8 Dose 1 on Week 0


title: Whole blood, SLE Patient 88 Dose 5 on Week 24; IFN-K

description:
EP777423A30
A2786_2514

source_name: SLE Patient 88 Dose 5 on Week 24

value: Patient 88


title: Whole blood, SLE patient 67 Follow-up on Week 36, placebo

description:
EP080731B08
A2786_2511

source_name: SLE Patient 67 Follow-up on Week 36

value: Patient 67


title: Whole blood, SLE patient 13 Dose 5 on Week 24, placebo

description:
AP111401B08
A2786_2503

source_name: SLE Patient 13 Dose 5 on Week 24

value: Patient 13


title: Whole blood, SLE Patient 124 Follow-up on Week 36 ; IFN-K

description:
AP990289A08
A2786_2498

source_name: SLE Patient 124 Follow-up on Week 36

value: Patient 124


title: Whole blood, SLE Patient 124 Dose 1 on Week 0; IFN-K

description:
AP525560A07
A2786_2494

source_name: SLE Patient 124 Dose 1 on Week 0


title: Whole blood, SLE patient 13 Follow-up on Week 36, placebo

description:
AP111413B08
A2786_2495

source_name: SLE Patient 13 Follow-up on Week 36


title: Whole blood, SLE patient 13 Dose 1 on Week 0, placebo

description:
AP212842A07
A2786_2493

source_name: SLE Patient 13 Dose 1 on Week 0


title: Whole blood, SLE Patient 124 Dose 5 on Week 24 ; IFN-K

description:
AP990279A08
A2786_2491

source_name: SLE Patient 124 Dose 5 on Week 24


title: Whole blood, SLE Patient 123 Dose 1 on Week 0; IFN-K

description:
AP525562A07
A2786_2490

source_name: SLE Patient 123 Dose 1 on Week 0


title: Whole blood, SLE Patient 109 Dose 1 on Week 0; IFN-K

description:
AP329187A07
A2786_2492

source_name: SLE Patient 109 Dose 1 on Week 0


title: Whole blood, SLE Patient 123 Dose 4 on Week 12 ; IFN-K

description:
AP670107A08
A2786_2486

source_name: SLE Patient 123 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 96 Dose 4 on Week 12 ; IFN-K

description:
AP637782A08
A2786_2488

source_name: SLE Patient 96 Dose 4 on Week 12

value: Patient 96


title: Whole blood, SLE Patient 126 Dose 4 on Week 12; IFN-K

description:
AP488882A07
A2786_2477

source_name: SLE Patient 126 Dose 4 on Week 12

value: SLE

value: Patient 126


title: Whole blood, SLE patient 13 Dose 4 on Week 12, placebo

description:
AP637787A08
A2786_2485

source_name: SLE Patient 13 Dose 4 on Week 12

value: PBO


title: Whole blood, SLE patient 39 Dose 5 on Week 24, placebo

description:
AP683822A29
A2786_2473

source_name: SLE Patient 39 Dose 5 on Week 24

value: Blood

value: Patient 39


title: Whole blood, SLE Patient 108 Dose 4 on Week 12; IFN-K

description:
AP329199A07
A2786_2474

source_name: SLE Patient 108 Dose 4 on Week 12

value: Patient 108


title: Whole blood, SLE Patient 126 Dose 5 on Week 24 ; IFN-K

description:
AP683821A08
A2786_2472

source_name: SLE Patient 126 Dose 5 on Week 24


title: Whole blood, SLE patient 12 Follow-up on Week 36, placebo

description:
AP111415B08
A2786_2479

source_name: SLE Patient 12 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 12


title: Whole blood, SLE Patient 96 Dose 1 on Week 0; IFN-K

description:
AP156984A29
A2786_2726

source_name: SLE Patient 96 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE patient 39 Dose 4 on Week 12, placebo

description:
AP119277A07
A2786_2476

source_name: SLE Patient 39 Dose 4 on Week 12


title: Whole blood, SLE patient 12 Dose 4 on Week 12, placebo

description:
AP620480A33
A2786_2480

source_name: SLE Patient 12 Dose 4 on Week 12


title: Whole blood, SLE patient 27 Dose 4 on Week 12, placebo

description:
AP431596A28
A2786_2481

source_name: SLE Patient 27 Dose 4 on Week 12

value: Patient 27


title: Whole blood, SLE patient 27 Follow-up on Week 36, placebo

description:
AP938625A07
A2786_2478

source_name: SLE Patient 27 Follow-up on Week 36


title: Whole blood, SLE patient 8 Dose 4 on Week 12, placebo

description:
AP699466A08
A2786_2483

source_name: SLE Patient 8 Dose 4 on Week 12

value: Patient 8


title: Whole blood, SLE patient 25 Dose 4 on Week 12, placebo

description:
AP329201A07
A2786_2475

source_name: SLE Patient 25 Dose 4 on Week 12

value: Patient 25


title: Whole blood, SLE Patient 113 Dose 5 on Week 24; IFN-K

description:
AP804653A07
A2786_2470

source_name: SLE Patient 113 Dose 5 on Week 24

value: IFN-K

value: Dose 5 on Week 24

value: Patient 113


title: Whole blood, SLE patient 27 Dose 1 on Week 0, placebo

description:
AP118372A07
A2786_2465

source_name: SLE Patient 27 Dose 1 on Week 0


title: Whole blood, SLE Patient 108 Dose 1 on Week 0; IFN-K

description:
AP329188A07
A2786_2463

source_name: SLE Patient 108 Dose 1 on Week 0


title: Whole blood, SLE patient 25 Dose 5 on Week 24, placebo

description:
AP329223A08
A2786_2468

source_name: SLE Patient 25 Dose 5 on Week 24


title: Whole blood, SLE patient 27 Dose 5 on Week 24, placebo

description:
AP804652A07
A2786_2471

source_name: SLE Patient 27 Dose 5 on Week 24


title: Whole blood, SLE Patient 124 Dose 4 on Week 12 ; IFN-K

description:
AP670111A08
A2786_2487

source_name: SLE Patient 124 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 124


title: Whole blood, SLE Patient 126 Dose 1 on Week 0; IFN-K

description:
AP119263A07
A2786_2467

source_name: SLE Patient 126 Dose 1 on Week 0

value: SLE


title: Whole blood, SLE Patient 109 Dose 4 on Week 12; IFN-K

description:
AP329200A07
A2786_2484

source_name: SLE Patient 109 Dose 4 on Week 12

value: Patient 109


title: Whole blood, SLE Patient 89 Dose 1 on Week 0; IFN-K

description:
AP198479A07
A2786_2464

source_name: SLE Patient 89 Dose 1 on Week 0

value: Patient 89


title: Whole blood, SLE Patient 164 Follow-up on Week 36 ; IFN-K

description:
SP292854A29
A2786_2482

source_name: SLE Patient 164 Follow-up on Week 36

value: Blood

value: Patient 164


title: Whole blood, SLE Patient 108 Dose 5 on Week 24; IFN-K

description:
AP329202A07
A2786_2469

source_name: SLE Patient 108 Dose 5 on Week 24

value: Patient 108


title: Whole blood, SLE Patient 89 Follow-up on Week 36; IFN-K

description:
AP020575B08
A2786_2461

source_name: SLE Patient 89 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 113 Dose 1 on Week 0; IFN-K

description:
AP118371A07
A2786_2466

source_name: SLE Patient 113 Dose 1 on Week 0


title: Whole blood, SLE patient 25 Dose 1 on Week 0, placebo

description:
AP329189A07
A2786_2462

source_name: SLE Patient 25 Dose 1 on Week 0

value: PBO


title: Whole blood, SLE patient 39 Dose 1 on Week 0, placebo

description:
AI750719-7
A2786_2459

source_name: SLE Patient 39 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 39


title: Whole blood, SLE patient 12 Dose 5 on Week 24, placebo

description:
AP620479A08
A2786_2453

source_name: SLE Patient 12 Dose 5 on Week 24

value: Patient 12


title: Whole blood, SLE Patient 113 Dose 4 on Week 12; IFN-K

description:
AP431592A07
A2786_2458

source_name: SLE Patient 113 Dose 4 on Week 12


title: Whole blood, SLE patient 12 Dose 1 on Week 0, placebo

description:
AP156985A07
A2786_2455

source_name: SLE Patient 12 Dose 1 on Week 0


title: Whole blood, SLE Patient 108 Follow-up on Week 36; IFN-K

description:
AP134052B07
A2786_2452

source_name: SLE Patient 108 Follow-up on Week 36


title: Whole blood, SLE Patient 164 Dose 1 on Week 0; IFN-K

description:
SP061480A08
A2786_2434

source_name: SLE Patient 164 Dose 1 on Week 0


title: Whole blood, SLE patient 46 Dose 4 on Week 12, placebo

description:
SP221250A08
A2786_2438

source_name: SLE Patient 46 Dose 4 on Week 12

value: Patient 46


title: Whole blood, SLE Patient 89 Dose 4 on Week 12 ; IFN-K

description:
AP641655A08
A2786_2457

source_name: SLE Patient 89 Dose 4 on Week 12

value: IFN-K


title: Whole blood, SLE Patient 134 Dose 5 on Week 24 ; IFN-K

description:
SP146660A08
A2786_2439

source_name: SLE Patient 134 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 134


title: Whole blood, SLE patient 49 Follow-up on Week 36, placebo

description:
SP220482A08
A2786_2431

source_name: SLE Patient 49 Follow-up on Week 36

value: Patient 49


title: Whole blood, SLE Patient 159 Dose 1 on Week 0; IFN-K

description:
SP068248A07
A2786_2446

source_name: SLE Patient 159 Dose 1 on Week 0

value: Patient 159


title: Whole blood, SLE Patient 134 Dose 1 on Week 0; IFN-K

description:
SP054782A07
A2786_2444

source_name: SLE Patient 134 Dose 1 on Week 0

value: SLE


title: Whole blood, SLE Patient 113 Follow-up on Week 36; IFN-K

description:
AP938624A29
A2786_2449

source_name: SLE Patient 113 Follow-up on Week 36

value: Patient 113


title: Whole blood, SLE Patient 159 Follow-up on Week 36 ; IFN-K

description:
SP255082A08
A2786_2448

source_name: SLE Patient 159 Follow-up on Week 36


title: Whole blood, SLE patient 44 Dose 1 on Week 0, placebo

description:
SP054675A07
A2786_2445

source_name: SLE Patient 44 Dose 1 on Week 0

value: Patient 44


title: Whole blood, SLE patient 25 Follow-up on Week 36, placebo

description:
AP134053B07
A2786_2451

source_name: SLE Patient 25 Follow-up on Week 36

value: Blood

value: Patient 25


title: Whole blood, SLE Patient 126 Follow-up on Week 36 ; IFN-K

description:
AP683826A08
A2786_2460

source_name: SLE Patient 126 Follow-up on Week 36

value: Patient 126


title: Whole blood, SLE Patient 129 Follow-up on Week 36 ; IFN-K

description:
SP146698A08
A2786_2436

source_name: SLE Patient 129 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 129


title: Whole blood, SLE patient 49 Dose 4 on Week 12, placebo

description:
SP146667A08
A2786_2442

source_name: SLE Patient 49 Dose 4 on Week 12

value: PBO

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 89 Dose 5 on Week 24; IFN-K

description:
AP825331A33
A2786_2450

source_name: SLE Patient 89 Dose 5 on Week 24

value: Patient 89


title: Whole blood, SLE Patient 159 Dose 4 on Week 12 ; IFN-K

description:
SP157687A08
A2786_2443

source_name: SLE Patient 159 Dose 4 on Week 12


title: Whole blood, SLE patient 49 Dose 5 on Week 24, placebo

description:
SP221093A08
A2786_2428

source_name: SLE Patient 49 Dose 5 on Week 24


title: Whole blood, SLE Patient 129 Dose 1 on Week 0; IFN-K

description:
SP054741A07
A2786_2441

source_name: SLE Patient 129 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 134 Dose 4 on Week 12 ; IFN-K

description:
SP146669A08
A2786_2435

source_name: SLE Patient 134 Dose 4 on Week 12

value: IFN-K


title: Whole blood, SLE Patient 129 Dose 5 on Week 24 ; IFN-K

description:
SP221180A08
A2786_2429

source_name: SLE Patient 129 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 164 Dose 4 on Week 12 ; IFN-K

description:
SP237007A08
A2786_2440

source_name: SLE Patient 164 Dose 4 on Week 12

value: Patient 164


title: Whole blood, SLE patient 39 Follow-up on Week 36, placebo

description:
AP683823A08
A2786_2456

source_name: SLE Patient 39 Follow-up on Week 36

value: Patient 39


title: Whole blood, SLE patient 44 Dose 4 on Week 12, placebo

description:
SP146729A08
A2786_2432

source_name: SLE Patient 44 Dose 4 on Week 12


title: Whole blood, SLE patient 44 Follow-up on Week 36, placebo

description:
SP220533A08
A2786_2447

source_name: SLE Patient 44 Follow-up on Week 36


title: Whole blood, SLE Patient 157 Dose 5 on Week 24 ; IFN-K

description:
EP523776A08
A2786_2425

source_name: SLE Patient 157 Dose 5 on Week 24

value: Patient 157


title: Whole blood, SLE patient 49 Dose 1 on Week 0, placebo

description:
SP054785A07
A2786_2437

source_name: SLE Patient 49 Dose 1 on Week 0

value: SLE

value: Patient 49


title: Whole blood, SLE Patient 164 Dose 5 on Week 24 ; IFN-K

description:
SP237008A08
A2786_2427

source_name: SLE Patient 164 Dose 5 on Week 24


title: Whole blood, SLE Patient 159 Dose 5 on Week 24 ; IFN-K

description:
SP206211A08
A2786_2430

source_name: SLE Patient 159 Dose 5 on Week 24

value: Patient 159


title: Whole blood, SLE Patient 129 Dose 4 on Week 12; IFN-K

description:
SP054757A07
A2786_2433

source_name: SLE Patient 129 Dose 4 on Week 12

value: Blood


title: Whole blood, SLE Patient 169 Dose 5 on Week 24 ; IFN-K

description:
EP287203A08
A2786_2424

source_name: SLE Patient 169 Dose 5 on Week 24

value: Patient 169


title: Whole blood, SLE Patient 134 Follow-up on Week 36 ; IFN-K

description:
SP220481A08
A2786_2426

source_name: SLE Patient 134 Follow-up on Week 36

value: Patient 134


title: Whole blood, SLE Patient 169 Dose 4 on Week 12 ; IFN-K

description:
EP370065A08
A2786_2417

source_name: SLE Patient 169 Dose 4 on Week 12


title: Whole blood, SLE Patient 100 Dose 5 on Week 24 ; IFN-K

description:
EP290306A08
A2786_2422

source_name: SLE Patient 100 Dose 5 on Week 24

value: Patient 100


title: Whole blood, SLE patient 75 Dose 5 on Week 24, placebo

description:
EP523560A08
A2786_2423

source_name: SLE Patient 75 Dose 5 on Week 24

value: Patient 75


title: Whole blood, SLE Patient 171 Dose 4 on Week 12 ; IFN-K

description:
EP381782A08
A2786_2416

source_name: SLE Patient 171 Dose 4 on Week 12

value: Patient 171


title: Whole blood, SLE Patient 100 Follow-up on Week 36 ; IFN-K

description:
EP290312A08
A2786_2420

source_name: SLE Patient 100 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE patient 76 Dose 5 on Week 24, placebo

description:
EP370066A08
A2786_2418

source_name: SLE Patient 76 Dose 5 on Week 24

value: PBO

value: Patient 76


title: Whole blood, SLE Patient 100 Dose 1 on Week 0; IFN-K

description:
EF267461-7
A2786_2419

source_name: SLE Patient 100 Dose 1 on Week 0

value: IFN-K

value: Dose 1 on Week 0


title: Whole blood, SLE patient 66 Dose 4 on Week 12, placebo

description:
EP092798A08
A2786_2410

source_name: SLE Patient 66 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 66


title: Whole blood, SLE Patient 171 Dose 5 on Week 24 ; IFN-K

description:
EP576875A08
A2786_2409

source_name: SLE Patient 171 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE patient 75 Dose 4 on Week 12, placebo

description:
EP370068A08
A2786_2413

source_name: SLE Patient 75 Dose 4 on Week 12

value: SLE


title: Whole blood, SLE patient 76 Dose 4 on Week 12, placebo

description:
EP370058A08
A2786_2414

source_name: SLE Patient 76 Dose 4 on Week 12


title: Whole blood, SLE Patient 157 Dose 4 on Week 12; IFN-K

description:
EP092796A08
A2786_2412

source_name: SLE Patient 157 Dose 4 on Week 12

value: Patient 157


title: Whole blood, SLE Patient 100 Dose 4 on Week 12 ; IFN-K

description:
EP290307A29
A2786_2421

source_name: SLE Patient 100 Dose 4 on Week 12


title: Whole blood, SLE Patient 169 Dose 1 on Week 0; IFN-K

description:
EP076747A07
A2786_2405

source_name: SLE Patient 169 Dose 1 on Week 0


title: Whole blood, SLE patient 77 Dose 5 on Week 24, placebo

description:
EP523561A29
A2786_2408

source_name: SLE Patient 77 Dose 5 on Week 24

value: Patient 77


title: Whole blood, SLE patient 66 Dose 1 on Week 0, placebo

description:
EP092777A29
A2786_2411

source_name: SLE Patient 66 Dose 1 on Week 0

value: Blood


title: Whole blood, SLE patient 77 Dose 4 on Week 12, placebo

description:
EP370064A08
A2786_2415

source_name: SLE Patient 77 Dose 4 on Week 12


title: Whole blood, SLE Patient 171 Dose 1 on Week 0; IFN-K

description:
EP239507A07
A2786_2406

source_name: SLE Patient 171 Dose 1 on Week 0


title: Whole blood, SLE Patient 157 Dose 1 on Week 0; IFN-K

description:
EP092778A07
A2786_2404

source_name: SLE Patient 157 Dose 1 on Week 0


title: Whole blood, SLE patient 76 Follow-up on Week 36, placebo

description:
EP792478A08
A2786_2402

source_name: SLE Patient 76 Follow-up on Week 36


title: Whole blood, SLE Patient 169 Follow-up on Week 36 ; IFN-K

description:
EP792479A08
A2786_2396

source_name: SLE Patient 169 Follow-up on Week 36

value: Patient 169


title: Whole blood, SLE patient 75 Follow-up on Week 36, placebo

description:
EP792471A08
A2786_2400

source_name: SLE Patient 75 Follow-up on Week 36


title: Whole blood, SLE patient 75 Dose 1 on Week 0, placebo

description:
EP076746A07
A2786_2394

source_name: SLE Patient 75 Dose 1 on Week 0


title: Whole blood, SLE patient 66 Dose 5 on Week 24, placebo

description:
EP523777A29
A2786_2407

source_name: SLE Patient 66 Dose 5 on Week 24


title: Whole blood, SLE Patient 166 Dose 1 on Week 0; IFN-K

description:
AP212701A08
A2786_2392

source_name: SLE Patient 166 Dose 1 on Week 0

value: Patient 166


title: Whole blood, SLE Patient 166 Follow-up on Week 36; IFN-K

description:
AP371222B21
A2786_2390

source_name: SLE Patient 166 Follow-up on Week 36


title: Whole blood, SLE Patient 171 Follow-up on Week 36 ; IFN-K

description:
EP664474A30
A2786_2658

source_name: SLE Patient 171 Follow-up on Week 36


title: Whole blood, SLE Patient 166 Dose 5 on Week 24; IFN-K

description:
AP827844A07
A2786_2388

source_name: SLE Patient 166 Dose 5 on Week 24


title: Whole blood, SLE patient 76 Dose 1 on Week 0, placebo

description:
EP076748A29
A2786_2399

source_name: SLE Patient 76 Dose 1 on Week 0


title: Whole blood, SLE patient 77 Dose 1 on Week 0, placebo

description:
EP076742A29
A2786_2395

source_name: SLE Patient 77 Dose 1 on Week 0


title: Whole blood, SLE Patient 166 Dose 4 on Week 12; IFN-K

description:
AP829227A07
A2786_2386

source_name: SLE Patient 166 Dose 4 on Week 12


title: Whole blood, SLE patient 70 Dose 4 on Week 12, placebo

description:
AP564783A07
A2786_2393

source_name: SLE Patient 70 Dose 4 on Week 12

value: Patient 70


title: Whole blood, SLE patient 77 Follow-up on Week 36, placebo

description:
EP792480A08
A2786_2403

source_name: SLE Patient 77 Follow-up on Week 36


title: Whole blood, SLE patient 66 Follow-up on Week 36, placebo

description:
EP092789A08
A2786_2398

source_name: SLE Patient 66 Follow-up on Week 36


title: Whole blood, SLE Patient 95 Dose 1 on Week 0; IFN-K

description:
AI667569-7
A2786_2379

source_name: SLE Patient 95 Dose 1 on Week 0

value: Patient 95


title: Whole blood, SLE patient 70 Dose 1 on Week 0, placebo

description:
AP188425A08
A2786_2391

source_name: SLE Patient 70 Dose 1 on Week 0


title: Whole blood, SLE patient 7 Follow-up on Week 36, placebo

description:
AP699483A08
A2786_2383

source_name: SLE Patient 7 Follow-up on Week 36

value: Patient 7


title: Whole blood, SLE Patient 118 Dose 5 on Week 24; IFN-K

description:
AP451376A07
A2786_2376

source_name: SLE Patient 118 Dose 5 on Week 24

value: Patient 118


title: Whole blood, SLE patient 36 Dose 5 on Week 24, placebo

description:
AP386656A07
A2786_2377

source_name: SLE Patient 36 Dose 5 on Week 24

value: PBO

value: Patient 36


title: Whole blood, SLE Patient 157 Follow-up on Week 36 ; IFN-K

description:
EP523787A08
A2786_2397

source_name: SLE Patient 157 Follow-up on Week 36

value: IFN-K

value: Follow-up on Week 36


title: Whole blood, SLE patient 70 Follow-up on Week 36, placebo

description:
AP765642A07
A2786_2389

source_name: SLE Patient 70 Follow-up on Week 36


title: Whole blood, SLE Patient 122 Dose 5 on Week 24 ; IFN-K

description:
AP670104A08
A2786_2374

source_name: SLE Patient 122 Dose 5 on Week 24

value: Patient 122


title: Whole blood, SLE patient 70 Dose 5 on Week 24, placebo

description:
AP765633A08
A2786_2387

source_name: SLE Patient 70 Dose 5 on Week 24


title: Whole blood, SLE Patient 95 Follow-up on Week 36 ; IFN-K

description:
AP637803A08
A2786_2384

source_name: SLE Patient 95 Follow-up on Week 36


title: Whole blood, SLE patient 36 Dose 4 on Week 12, placebo

description:
AP386651A07
A2786_2369

source_name: SLE Patient 36 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 121 Follow-up on Week 36 ; IFN-K

description:
AP670119A08
A2786_2382

source_name: SLE Patient 121 Follow-up on Week 36

value: Patient 121


title: Whole blood, SLE patient 36 Follow-up on Week 36, placebo

description:
AP670118A08
A2786_2380

source_name: SLE Patient 36 Follow-up on Week 36

value: SLE


title: Whole blood, SLE Patient 121 Dose 4 on Week 12; IFN-K

description:
AP386654A07
A2786_2370

source_name: SLE Patient 121 Dose 4 on Week 12


title: Whole blood, SLE patient 7 Dose 4 on Week 12, placebo

description:
AP143613A07
A2786_2371

source_name: SLE Patient 7 Dose 4 on Week 12


title: Whole blood, SLE patient 14 Dose 5 on Week 24, placebo

description:
AP659502A08
A2786_2378

source_name: SLE Patient 14 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 14


title: Whole blood, SLE Patient 118 Dose 1 on Week 0; IFN-K

description:
AP119133A07
A2786_2364

source_name: SLE Patient 118 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Blood


title: Whole blood, SLE patient 14 Dose 4 on Week 12, placebo

description:
AP411993A07
A2786_2356

source_name: SLE Patient 14 Dose 4 on Week 12


title: Whole blood, SLE Patient 122 Dose 1 on Week 0; IFN-K

description:
AI782186-7
A2786_2361

source_name: SLE Patient 122 Dose 1 on Week 0


title: Whole blood, SLE patient 14 Follow-up on Week 36, placebo

description:
AP042715B08
A2786_2355

source_name: SLE Patient 14 Follow-up on Week 36


title: Whole blood, SLE patient 7 Dose 1 on Week 0, placebo

description:
AP143603A07
A2786_2367

source_name: SLE Patient 7 Dose 1 on Week 0


title: Whole blood, SLE Patient 118 Dose 4 on Week 12; IFN-K

description:
AP119139A28
A2786_2363

source_name: SLE Patient 118 Dose 4 on Week 12


title: Whole blood, SLE Patient 122 Follow-up on Week 36 ; IFN-K

description:
AP670116A08
A2786_2353

source_name: SLE Patient 122 Follow-up on Week 36


title: Whole blood, SLE Patient 95 Dose 4 on Week 12; IFN-K

description:
AI715912-35
A2786_2372

source_name: SLE Patient 95 Dose 4 on Week 12


title: Whole blood, SLE patient 14 Dose 1 on Week 0, placebo

description:
AP276005A29
A2786_2568

source_name: SLE Patient 14 Dose 1 on Week 0


title: Whole blood, SLE patient 38 Dose 5 on Week 24, placebo

description:
AP488879A07
A2786_2375

source_name: SLE Patient 38 Dose 5 on Week 24

value: Patient 38


title: Whole blood, SLE patient 38 Dose 1 on Week 0, placebo

description:
AI750721-29
A2786_2366

source_name: SLE Patient 38 Dose 1 on Week 0


title: Whole blood, SLE patient 36 Dose 1 on Week 0, placebo

description:
AI576236-7
A2786_2365

source_name: SLE Patient 36 Dose 1 on Week 0


title: Whole blood, SLE Patient 121 Dose 1 on Week 0; IFN-K

description:
AI576237-7
A2786_2362

source_name: SLE Patient 121 Dose 1 on Week 0


title: Whole blood, SLE patient 7 Dose 5 on Week 24, placebo

description:
AP511442A28
A2786_2545

source_name: SLE Patient 7 Dose 5 on Week 24


title: Whole blood, SLE Patient 95 Dose 5 on Week 24; IFN-K

description:
AP212851A07
A2786_2373

source_name: SLE Patient 95 Dose 5 on Week 24


title: Whole blood, SLE Patient 133 Dose 1 on Week 0; IFN-K

description:
S5602795-7
A2786_2346

source_name: SLE Patient 133 Dose 1 on Week 0

value: Patient 133


title: Whole blood, SLE Patient 122 Dose 4 on Week 12; IFN-K

description:
AI782207-7
A2786_2357

source_name: SLE Patient 122 Dose 4 on Week 12


title: Whole blood, SLE Patient 161 Dose 4 on Week 12; IFN-K

description:
SP063846A07
A2786_2340

source_name: SLE Patient 161 Dose 4 on Week 12

value: Patient 161


title: Whole blood, SLE Patient 133 Dose 5 on Week 24 ; IFN-K

description:
SP146666A29
A2786_2343

source_name: SLE Patient 133 Dose 5 on Week 24


title: Whole blood, SLE Patient 132 Dose 4 on Week 12; IFN-K

description:
SP054809A07
A2786_2337

source_name: SLE Patient 132 Dose 4 on Week 12

value: Patient 132


title: Whole blood, SLE patient 72 Dose 5 on Week 24, placebo

description:
EP523558A08
A2786_2336

source_name: SLE Patient 72 Dose 5 on Week 24

value: Patient 72


title: Whole blood, SLE Patient 154 Dose 5 on Week 24 ; IFN-K

description:
EP314693A08
A2786_2333

source_name: SLE Patient 154 Dose 5 on Week 24

value: Patient 154


title: Whole blood, SLE Patient 127 Follow-up on Week 36 ; IFN-K

description:
SP220529A08
A2786_2352

source_name: SLE Patient 127 Follow-up on Week 36

value: Patient 127


title: Whole blood, SLE patient 81 Dose 5 on Week 24, placebo

description:
EP381783A08
A2786_2335

source_name: SLE Patient 81 Dose 5 on Week 24

value: PBO

value: Patient 81


title: Whole blood, SLE Patient 121 Dose 5 on Week 24; IFN-K

description:
AP386652A07
A2786_2359

source_name: SLE Patient 121 Dose 5 on Week 24

value: IFN-K


title: Whole blood, SLE patient 38 Follow-up on Week 36, placebo

description:
AP683828A08
A2786_2354

source_name: SLE Patient 38 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 132 Follow-up on Week 36 ; IFN-K

description:
SP220480A08
A2786_2349

source_name: SLE Patient 132 Follow-up on Week 36


title: Whole blood, SLE patient 38 Dose 4 on Week 12, placebo

description:
AP119273A28
A2786_2629

source_name: SLE Patient 38 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE patient 82 Dose 5 on Week 24, placebo

description:
EP576874A08
A2786_2330

source_name: SLE Patient 82 Dose 5 on Week 24

value: SLE

value: Patient 82


title: Whole blood, SLE Patient 168 Dose 5 on Week 24 ; IFN-K

description:
EP370060A08
A2786_2331

source_name: SLE Patient 168 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 168


title: Whole blood, SLE Patient 161 Follow-up on Week 36; IFN-K

description:
SP314207A07
A2786_2351

source_name: SLE Patient 161 Follow-up on Week 36

value: Blood


title: Whole blood, SLE Patient 127 Dose 5 on Week 24 ; IFN-K

description:
SP146727A08
A2786_2342

source_name: SLE Patient 127 Dose 5 on Week 24


title: Whole blood, SLE patient 73 Dose 5 on Week 24, placebo

description:
EP523559A08
A2786_2328

source_name: SLE Patient 73 Dose 5 on Week 24

value: Patient 73


title: Whole blood, SLE Patient 127 Dose 1 on Week 0; IFN-K

description:
SP054677A07
A2786_2348

source_name: SLE Patient 127 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE patient 74 Dose 5 on Week 24, placebo

description:
EP370061A08
A2786_2327

source_name: SLE Patient 74 Dose 5 on Week 24

value: Patient 74


title: Whole blood, SLE patient 73 Dose 1 on Week 0, placebo

description:
EP076745A07
A2786_2325

source_name: SLE Patient 73 Dose 1 on Week 0


title: Whole blood, SLE Patient 127 Dose 4 on Week 12; IFN-K

description:
SP054693A07
A2786_2339

source_name: SLE Patient 127 Dose 4 on Week 12


title: Whole blood, SLE patient 74 Dose 4 on Week 12, placebo

description:
EP370069A08
A2786_2326

source_name: SLE Patient 74 Dose 4 on Week 12


title: Whole blood, SLE Patient 161 Dose 5 on Week 24 ; IFN-K

description:
SP253800A28
A2786_2655

source_name: SLE Patient 161 Dose 5 on Week 24

value: Patient 161


title: Whole blood, SLE patient 22 Dose 4 on Week 12, placebo

description:
EP090309A08
A2786_2320

source_name: SLE Patient 22 Dose 4 on Week 12

value: Patient 22


title: Whole blood, SLE patient 81 Dose 1 on Week 0, placebo

description:
EP075560A07
A2786_2319

source_name: SLE Patient 81 Dose 1 on Week 0


title: Whole blood, SLE Patient 132 Dose 1 on Week 0; IFN-K

description:
S5602794-7
A2786_2345

source_name: SLE Patient 132 Dose 1 on Week 0

value: Patient 132


title: Whole blood, SLE Patient 168 Dose 1 on Week 0; IFN-K

description:
EP067498A29
A2786_2315

source_name: SLE Patient 168 Dose 1 on Week 0


title: Whole blood, SLE patient 60 Dose 1 on Week 0, placebo

description:
EF256012-7
A2786_2314

source_name: SLE Patient 60 Dose 1 on Week 0

value: Patient 60


title: Whole blood, SLE Patient 132 Dose 5 on Week 24 ; IFN-K

description:
SP146663A08
A2786_2341

source_name: SLE Patient 132 Dose 5 on Week 24


title: Whole blood, SLE Patient 167 Dose 1 on Week 0; IFN-K

description:
EP076744A07
A2786_2656

source_name: SLE Patient 167 Dose 1 on Week 0

value: Patient 167


title: Whole blood, SLE patient 79 Dose 5 on Week 24, placebo

description:
EP381781A08
A2786_2332

source_name: SLE Patient 79 Dose 5 on Week 24

value: PBO

value: Patient 79


title: Whole blood, SLE Patient 133 Dose 4 on Week 12; IFN-K

description:
SP054810A07
A2786_2338

source_name: SLE Patient 133 Dose 4 on Week 12

value: IFN-K

value: Patient 133


title: Whole blood, SLE patient 72 Follow-up on Week 36, placebo

description:
EP792476A08
A2786_2309

source_name: SLE Patient 72 Follow-up on Week 36

value: SLE

value: Follow-up on Week 36

value: Patient 72


title: Whole blood, SLE Patient 168 Follow-up on Week 36 ; IFN-K

description:
EP792473A08
A2786_2311

source_name: SLE Patient 168 Follow-up on Week 36

value: Patient 168


title: Whole blood, SLE Patient 133 Follow-up on Week 36 ; IFN-K

description:
SP220485A08
A2786_2350

source_name: SLE Patient 133 Follow-up on Week 36

value: Blood


title: Whole blood, SLE patient 73 Follow-up on Week 36, placebo

description:
EP792475A08
A2786_2308

source_name: SLE Patient 73 Follow-up on Week 36

value: Patient 73


title: Whole blood, SLE patient 22 Follow-up on Week 36, placebo

description:
EP090321A08
A2786_2329

source_name: SLE Patient 22 Follow-up on Week 36


title: Whole blood, SLE patient 80 Dose 1 on Week 0, placebo

description:
EP075559A07
A2786_2321

source_name: SLE Patient 80 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 80


title: Whole blood, SLE Patient 154 Follow-up on Week 36 ; IFN-K

description:
EP314698A08
A2786_2305

source_name: SLE Patient 154 Follow-up on Week 36

value: Patient 154


title: Whole blood, SLE patient 60 Dose 4 on Week 12, placebo

description:
EP141111A08
A2786_2317

source_name: SLE Patient 60 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 167 Dose 5 on Week 24 ; IFN-K

description:
EP287202A08
A2786_2304

source_name: SLE Patient 167 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE patient 82 Dose 1 on Week 0, placebo

description:
EP239508A07
A2786_2324

source_name: SLE Patient 82 Dose 1 on Week 0

value: Patient 82


title: Whole blood, SLE Patient 161 Dose 1 on Week 0; IFN-K

description:
SP034079A29
A2786_2347

source_name: SLE Patient 161 Dose 1 on Week 0

value: Patient 161


title: Whole blood, SLE patient 79 Dose 1 on Week 0, placebo

description:
EP067488A07
A2786_2323

source_name: SLE Patient 79 Dose 1 on Week 0

value: PBO


title: Whole blood, SLE Patient 154 Dose 1 on Week 0; IFN-K

description:
EF256263-7
A2786_2322

source_name: SLE Patient 154 Dose 1 on Week 0


title: Whole blood, SLE Patient 118 Follow-up on Week 36 ; IFN-K

description:
AP577191A08
A2786_2381

source_name: SLE Patient 118 Follow-up on Week 36

value: Patient 118


title: Whole blood, SLE patient 73 Dose 4 on Week 12, placebo

description:
EP370070A08
A2786_2306

source_name: SLE Patient 73 Dose 4 on Week 12


title: Whole blood, SLE patient 80 Dose 4 on Week 12, placebo

description:
EP381778A08
A2786_2301

source_name: SLE Patient 80 Dose 4 on Week 12


title: Whole blood, SLE patient 60 Follow-up on Week 36, placebo

description:
EP141117A08
A2786_2307

source_name: SLE Patient 60 Follow-up on Week 36

value: Patient 60


title: Whole blood, SLE patient 74 Dose 1 on Week 0, placebo

description:
EP076750A07
A2786_2316

source_name: SLE Patient 74 Dose 1 on Week 0

value: Patient 74


title: Whole blood, SLE patient 60 Dose 5 on Week 24, placebo

description:
EP141112A08
A2786_2303

source_name: SLE Patient 60 Dose 5 on Week 24

value: SLE


title: Whole blood, SLE patient 82 Dose 4 on Week 12, placebo

description:
EP381787A08
A2786_2299

source_name: SLE Patient 82 Dose 4 on Week 12


title: Whole blood, SLE Patient 167 Dose 4 on Week 12 ; IFN-K

description:
EP370071A08
A2786_2298

source_name: SLE Patient 167 Dose 4 on Week 12

value: IFN-K

value: Patient 167


title: Whole blood, SLE Patient 154 Dose 4 on Week 12 ; IFN-K

description:
EF196229-33
A2786_2652

source_name: SLE Patient 154 Dose 4 on Week 12


title: Whole blood, SLE patient 80 Follow-up on Week 36, placebo

description:
EP664472A08
A2786_2310

source_name: SLE Patient 80 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE patient 79 Follow-up on Week 36, placebo

description:
EP664471A08
A2786_2291

source_name: SLE Patient 79 Follow-up on Week 36

value: Blood

value: Patient 79


title: Whole blood, SLE patient 81 Dose 4 on Week 12, placebo

description:
EP381786A08
A2786_2300

source_name: SLE Patient 81 Dose 4 on Week 12

value: Patient 81


title: Whole blood, SLE patient 79 Dose 4 on Week 12, placebo

description:
EP381784A08
A2786_2297

source_name: SLE Patient 79 Dose 4 on Week 12


title: Whole blood, SLE Patient 160 Dose 4 on Week 12 ; IFN-K

description:
SP070517A29
A2786_2287

source_name: SLE Patient 160 Dose 4 on Week 12

value: Patient 160


title: Whole blood, SLE Patient 168 Dose 4 on Week 12 ; IFN-K

description:
EP370067A08
A2786_2302

source_name: SLE Patient 168 Dose 4 on Week 12

value: Patient 168


title: Whole blood, SLE patient 72 Dose 4 on Week 12, placebo

description:
EP287200A08
A2786_2294

source_name: SLE Patient 72 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 72


title: Whole blood, SLE patient 22 Dose 5 on Week 24, placebo

description:
EP090311A08
A2786_2295

source_name: SLE Patient 22 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 22


title: Whole blood, SLE patient 82 Follow-up on Week 36, placebo

description:
EP664473A30
A2786_2657

source_name: SLE Patient 82 Follow-up on Week 36

value: PBO

value: Patient 82


title: Whole blood, SLE Patient 167 Follow-up on Week 36 ; IFN-K

description:
EP792474A08
A2786_2293

source_name: SLE Patient 167 Follow-up on Week 36


title: Whole blood, SLE patient 81 Follow-up on Week 36, placebo

description:
EP664475A08
A2786_2290

source_name: SLE Patient 81 Follow-up on Week 36


title: Whole blood, SLE patient 74 Follow-up on Week 36, placebo

description:
EP792472A08
A2786_2292

source_name: SLE Patient 74 Follow-up on Week 36


title: Whole blood, SLE patient 43 Dose 4 on Week 12, placebo

description:
S5634031-28
A2786_2631

source_name: SLE Patient 43 Dose 4 on Week 12

value: Patient 43


title: Whole blood, SLE Patient 163 Dose 4 on Week 12; IFN-K

description:
SP049818A07
A2786_2282

source_name: SLE Patient 163 Dose 4 on Week 12

value: Patient 163


title: Whole blood, SLE patient 72 Dose 1 on Week 0, placebo

description:
EP076749A07
A2786_2318

source_name: SLE Patient 72 Dose 1 on Week 0

value: SLE

value: Dose 1 on Week 0


title: Whole blood, SLE patient 48 Dose 4 on Week 12, placebo

description:
S5634549-28
A2786_2283

source_name: SLE Patient 48 Dose 4 on Week 12

value: Patient 48


title: Whole blood, SLE patient 43 Dose 5 on Week 24, placebo

description:
SP054695A07
A2786_2288

source_name: SLE Patient 43 Dose 5 on Week 24


title: Whole blood, SLE patient 80 Dose 5 on Week 24, placebo

description:
EP381780A08
A2786_2334

source_name: SLE Patient 80 Dose 5 on Week 24

value: Patient 80


title: Whole blood, SLE patient 68 Dose 4 on Week 12, placebo

description:
SP034761A07
A2786_2284

source_name: SLE Patient 68 Dose 4 on Week 12

value: Blood

value: Patient 68


title: Whole blood, SLE Patient 160 Follow-up on Week 36 ; IFN-K

description:
SP185907A29
A2786_2654

source_name: SLE Patient 160 Follow-up on Week 36

value: IFN-K

value: Follow-up on Week 36


title: Whole blood, SLE patient 22 Dose 1 on Week 0, placebo

description:
EE822797-7
A2786_2724

source_name: SLE Patient 22 Dose 1 on Week 0


title: Whole blood, SLE Patient 160 Dose 5 on Week 24 ; IFN-K

description:
SP070518A08
A2786_2267

source_name: SLE Patient 160 Dose 5 on Week 24

value: Patient 160


title: Whole blood, SLE Patient 128 Follow-up on Week 36; IFN-K

description:
SP107037A07
A2786_2268

source_name: SLE Patient 128 Follow-up on Week 36

value: Patient 128


title: Whole blood, SLE Patient 128 Dose 1 on Week 0; IFN-K

description:
S5602900-29
A2786_2275

source_name: SLE Patient 128 Dose 1 on Week 0


title: Whole blood, SLE Patient 128 Dose 4 on Week 12; IFN-K

description:
S5634116-7
A2786_2280

source_name: SLE Patient 128 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 163 Dose 1 on Week 0; IFN-K

description:
S5544087-7
A2786_2276

source_name: SLE Patient 163 Dose 1 on Week 0


title: Whole blood, SLE Patient 128 Dose 5 on Week 24; IFN-K

description:
SP054760A07
A2786_2265

source_name: SLE Patient 128 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 162 Dose 1 on Week 0; IFN-K

description:
S5544089-29
A2786_2273

source_name: SLE Patient 162 Dose 1 on Week 0

value: Patient 162


title: Whole blood, SLE patient 43 Follow-up on Week 36, placebo

description:
SP146734A08
A2786_2270

source_name: SLE Patient 43 Follow-up on Week 36

value: PBO


title: Whole blood, SLE Patient 163 Follow-up on Week 36; IFN-K

description:
SP068058A07
A2786_2272

source_name: SLE Patient 163 Follow-up on Week 36


title: Whole blood, SLE Patient 160 Dose 1 on Week 0; IFN-K

description:
S5612880-7
A2786_2279

source_name: SLE Patient 160 Dose 1 on Week 0


title: Whole blood, SLE Patient 162 Dose 4 on Week 12; IFN-K

description:
SP049820A07
A2786_2281

source_name: SLE Patient 162 Dose 4 on Week 12


title: Whole blood, SLE Patient 162 Dose 5 on Week 24; IFN-K

description:
SP049817A07
A2786_2264

source_name: SLE Patient 162 Dose 5 on Week 24


title: Whole blood, SLE patient 68 Follow-up on Week 36, placebo

description:
SP253798A07
A2786_2261

source_name: SLE Patient 68 Follow-up on Week 36


title: Whole blood, SLE Patient 163 Dose 5 on Week 24; IFN-K

description:
SP049819A07
A2786_2263

source_name: SLE Patient 163 Dose 5 on Week 24


title: Whole blood, SLE patient 68 Dose 5 on Week 24, placebo

description:
SP076584A07
A2786_2266

source_name: SLE Patient 68 Dose 5 on Week 24


title: Whole blood, SLE patient 43 Dose 1 on Week 0, placebo

description:
S5602924-29
A2786_2630

source_name: SLE Patient 43 Dose 1 on Week 0


title: Whole blood, SLE patient 48 Follow-up on Week 36, placebo

description:
SP146681A08
A2786_2269

source_name: SLE Patient 48 Follow-up on Week 36


title: Whole blood, SLE Patient 142 Follow-up on Week 36 ; IFN-K

description:
EP611250A08
A2786_2260

source_name: SLE Patient 142 Follow-up on Week 36

value: Patient 142


title: Whole blood, SLE patient 48 Dose 5 on Week 24, placebo

description:
SP054812A07
A2786_2262

source_name: SLE Patient 48 Dose 5 on Week 24


title: Whole blood, SLE Patient 155 Dose 5 on Week 24 ; IFN-K

description:
EP141109A08
A2786_2257

source_name: SLE Patient 155 Dose 5 on Week 24

value: Patient 155


title: Whole blood, SLE patient 23 Dose 5 on Week 24, placebo

description:
EF290997-8
A2786_2258

source_name: SLE Patient 23 Dose 5 on Week 24

value: Patient 23


title: Whole blood, SLE patient 59 Dose 1 on Week 0, placebo

description:
EE871395-7
A2786_2253

source_name: SLE Patient 59 Dose 1 on Week 0

value: SLE

value: Patient 59


title: Whole blood, SLE Patient 155 Dose 1 on Week 0; IFN-K

description:
EE871396-7
A2786_2251

source_name: SLE Patient 155 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 142 Dose 5 on Week 24 ; IFN-K

description:
EF347924-8
A2786_2259

source_name: SLE Patient 142 Dose 5 on Week 24


title: Whole blood, SLE patient 48 Dose 1 on Week 0, placebo

description:
S5602796-29
A2786_2274

source_name: SLE Patient 48 Dose 1 on Week 0

value: Patient 48


title: Whole blood, SLE Patient 155 Follow-up on Week 36 ; IFN-K

description:
EP141119A08
A2786_2252

source_name: SLE Patient 155 Follow-up on Week 36

value: Blood


title: Whole blood, SLE patient 68 Dose 1 on Week 0, placebo

description:
S5539163-7
A2786_2278

source_name: SLE Patient 68 Dose 1 on Week 0

value: Patient 68


title: Whole blood, SLE patient 59 Follow-up on Week 36, placebo

description:
EP141120A08
A2786_2249

source_name: SLE Patient 59 Follow-up on Week 36


title: Whole blood, SLE Patient 105 Follow-up on Week 36 ; IFN-K

description:
EP090320A08
A2786_2250

source_name: SLE Patient 105 Follow-up on Week 36

value: IFN-K

value: Patient 105


title: Whole blood, SLE Patient 155 Dose 4 on Week 12 ; IFN-K

description:
EF256018-8
A2786_2244

source_name: SLE Patient 155 Dose 4 on Week 12


title: Whole blood, SLE Patient 105 Dose 5 on Week 24 ; IFN-K

description:
EP090310A08
A2786_2247

source_name: SLE Patient 105 Dose 5 on Week 24


title: Multiplexed targets sequence pool CTCs(Cultured for 12h)-r

type: SRA

city: Toronto

first: Yuan

last: Ma

address: 144 College St.

country: Canada

institute: University of Toronto

description: CTCs(Cultured for 12h)-r

library_source: genomic

data_processing:
Sequenced data was processed and aligned by Geneious
Genome_build: mm9
Supplementary_files_format_and_content: Table2 Multiplexed target counts of the aligned results

molecule: genomic DNA

organism: Escherichia phage M13

source_name: CTCs(Cultured for 12h)-r

growth_protocol: The neutralized solution containing phage was then added to 5 mL of OmniMAX E coli cells (Invitrogen) at an OD600 of 0.6-0.8 in 2-YT broth, and incubated at 37 °C with shaking at 200 rpm for 30 min. M13KO7 helper phage (NEB) at a final concentration of 1010 /mL was added before further propagation for additional 45 min. The 5 mL cell mixture was finally added to 45 mL 2-YT supplemented with 100 µg/mL carbenicillin and 25 µg/mL kanamycin and incubated at 37 °C with shaking at 200 rpm for overnight.

extract_protocol:
Each 50 μL of PCR reaction included 25 μL of 2 × KAPA HiFi HotStart ReadyMix (Roche), 17 μL of dH2O, 6 μL Primer mix (2.5 μM final), 2 μL of phages (undiluted, 1/10 dilution, or 1/100 dilution).
PCR products were run on a 1 % agarose gel to confirm the size of the product (expected size: ~200 bp) and gel purified with QIAquick Gel Extraction Kit (Qiagen) following manufacturer’s protocol. Samples were submitted to Donnelly Sequencing Centre (University of Toronto) for next-generation sequencing (NGS) on a HiSeq4000 (Illumina).

treatment_protocol: To precipitate the amplified phages from the bacterial culture, 1/5 volume of PEG-NaCl was added to the supernatant after spinning the culture at 17,600 × g for 10 min. The tubes were then incubated on ice for 20 min and centrifuged at 17,600 × g for 2 min.

tag: cell type

value: CTCs(Cultured for 12h)-r


title: Whole blood, SLE Patient 105 Dose 1 on Week 0; IFN-K

description:
EE822796-29
A2786_2255

source_name: SLE Patient 105 Dose 1 on Week 0


title: Whole blood, SLE patient 23 Dose 4 on Week 12, placebo

description:
EF290998-8
A2786_2243

source_name: SLE Patient 23 Dose 4 on Week 12


title: Whole blood, SLE patient 23 Follow-up on Week 36, placebo

description:
EP503109A08
A2786_2248

source_name: SLE Patient 23 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 105 Dose 4 on Week 12; IFN-K

description:
EF323171-29
A2786_2245

source_name: SLE Patient 105 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 112 Follow-up on Week 36; IFN-K

description:
AP118396A29
A2786_2240

source_name: SLE Patient 112 Follow-up on Week 36

value: Patient 112


title: Whole blood, SLE Patient 107 Dose 5 on Week 24; IFN-K

description:
AP539033A28
A2786_2239

source_name: SLE Patient 107 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 107


title: Whole blood, SLE Patient 142 Dose 4 on Week 12 ; IFN-K

description:
EF347919-29
A2786_2246

source_name: SLE Patient 142 Dose 4 on Week 12

value: Patient 142


title: Whole blood, SLE patient 37 Follow-up on Week 36, placebo

description:
AP488903A29
A2786_2237

source_name: SLE Patient 37 Follow-up on Week 36

value: PBO

value: Patient 37


title: Whole blood, SLE patient 23 Dose 1 on Week 0, placebo

description:
EE695522-7
A2786_2254

source_name: SLE Patient 23 Dose 1 on Week 0

value: SLE

value: Patient 23


title: Whole blood, SLE Patient 162 Follow-up on Week 36; IFN-K

description:
SP156993A08
A2786_2271

source_name: SLE Patient 162 Follow-up on Week 36

value: Patient 162


title: Whole blood, SLE Patient 117 Follow-up on Week 36 ; IFN-K

description:
AP699323A08
A2786_2235

source_name: SLE Patient 117 Follow-up on Week 36

value: Patient 117


title: Whole blood, SLE Patient 142 Dose 1 on Week 0; IFN-K

description:
EE845606-7
A2786_2241

source_name: SLE Patient 142 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Blood


title: Whole blood, SLE Patient 125 Follow-up on Week 36; IFN-K

description:
AP488902A07
A2786_2236

source_name: SLE Patient 125 Follow-up on Week 36

value: IFN-K

value: Patient 125


title: Whole blood, SLE patient 59 Dose 4 on Week 12, placebo

description:
EF256017-8
A2786_2242

source_name: SLE Patient 59 Dose 4 on Week 12

value: Patient 59


title: Multiplexed targets sequence pool

description: Phage pool

source_name: Phage pool

value: Phage pool


title: Multiplexed targets sequence pool CTCs(Freshly captured)

description: CTCs(Freshly captured)

source_name: CTCs(Freshly captured)

value: CTCs(Freshly captured)


title: M13 H3 HDR sequence Cell Population H460


title: M13 H3 HDR sequence Cell Population K562


title: Whole blood, SLE patient 31 Follow-up on Week 36, placebo

description:
AP649049A07
A2786_2234

source_name: SLE Patient 31 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 31


title: M13 H3 HDR sequence Single Cell4


title: M13 H3 HDR sequence Single Cell3


title: Multiplexed targets sequence pool CTCs(Freshly captured)-r

description: CTCs(Freshly captured)-r

source_name: CTCs(Freshly captured)-r

value: CTCs(Freshly captured)-r


title: Whole blood, SLE patient 2 Follow-up on Week 36, placebo

description:
AP653143A30
A2786_2238

source_name: SLE Patient 2 Follow-up on Week 36

value: Patient 2


title: M13 H3 HDR sequence Single Cell2


title: Whole blood, SLE patient 29 Follow-up on Week 36, placebo

description:
AP168583A33
A2786_2595

source_name: SLE Patient 29 Follow-up on Week 36

value: PBO

value: Patient 29


title: Whole blood, SLE Patient 94 Follow-up on Week 36; IFN-K

description:
AP212887A07
A2786_2231

source_name: SLE Patient 94 Follow-up on Week 36

value: SLE

value: Patient 94


title: Whole blood, SLE patient 37 Dose 5 on Week 24, placebo

description:
AI750734-28
A2786_2628

source_name: SLE Patient 37 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 37


title: IKOCA_C: U87 coculture IKOCA

city: Bronx

first: Sean

last: McCutcheon

state: NY

address: 1410 Pelham Pwky S, Kennedy Center Rm. 840

department: Neuroscience

country: USA

institute: Albert Einstein College of Medicine

library_source: transcriptomic

data_processing:
Raw reads were subjected to an in-house program, ACGT101-miR (LC Sciences, Houston, Texas, USA) to remove adapter dimers, junk, low complexity, common RNA families (rRNA, tRNA, snRNA, snoRNA) and repeats
Subsequently, unique sequences with length in 18~26 nucleotide were mapped to specific species precursors in miRBase 22.0 by BLAST search to identify known miRNAs and novel 3p- and 5p- derived miRNAs
The unmapped sequences were BLASTed against the specific genomes, and the hairpin RNA structures containing sequences were predicated from the flank 80 nt sequences using RNAfold software (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi).
Supplementary_files_format_and_content: Excel files

organism: Mus musculus

source_name: U87 coculture IKOCA

growth_protocol: Cells were grown in DMEM supplemented with 10% FBS and 1% antibacterial-antimycotic

extract_protocol:
miRNA was isolated using the small RNA extraction kit:  ThermoFisher Scientific  #AM1560
Total RNA was extracted using Trizol reagent (Invitrogen, CA, USA) following the manufacturer's procedure. The total RNA quality and quantity were analysis of Bioanalyzer 2100 (Agilent, CA, USA) with RIN number >7.0. Approximately 1 ug of total RNA were used to prepare small RNA library according to protocol of TruSeq Small RNA Sample Prep Kits(Illumina, San Diego, USA). And then we performed the single-end sequencing 50bp on an Illumina Hiseq 2500 at the LC Sciences (Hangzhou, China)

treatment_protocol: Cells were cocultured for 24 hours.

tag: strain

value: Mouse (C57BL/6)

value: immortalized murine astrocytes

tag: cx43 expression

value: Cx43 KO


title: Whole blood, SLE Patient 117 Dose 5 on Week 24; IFN-K

description:
AP119141A28
A2786_2609

source_name: SLE Patient 117 Dose 5 on Week 24

value: IFN-K

value: Blood

value: Patient 117


title: M13 H3 HDR sequence Single Cell1


title: Whole blood, SLE Patient 112 Dose 5 on Week 24; IFN-K

description:
AP431594A07
A2786_2228

source_name: SLE Patient 112 Dose 5 on Week 24

value: Patient 112


title: Whole blood, SLE Patient 94 Dose 5 on Week 24; IFN-K

description:
AI715911-7
A2786_2227

source_name: SLE Patient 94 Dose 5 on Week 24


title: IWCA_C: U87 coculture IWCA

source_name: U87 coculture IWCA

value: Cx43 WT


title: IWCA: Wild type Astrocytes

source_name: Wild type Astrocytes


title: IKOCA: Cx43 KO Astrocytes

source_name: Cx43 KO Astrocytes


title: Multiplexed targets sequence pool CTCs(Cultured for 12h)

description: CTCs(Cultured for 12h)

source_name: CTCs(Cultured for 12h)

value: CTCs(Cultured for 12h)


title: Whole blood, SLE patient 3 Follow-up on Week 36, placebo

description:
AP641659A08
A2786_2225

source_name: SLE Patient 3 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 3


title: Whole blood, SLE Patient 114 Follow-up on Week 36; IFN-K

description:
AP506301A07
A2786_2226

source_name: SLE Patient 114 Follow-up on Week 36

value: Patient 114


title: Whole blood, SLE patient 3 Dose 1 on Week 0, placebo

description:
AI576340-29
A2786_2223

source_name: SLE Patient 3 Dose 1 on Week 0

value: PBO

value: Dose 1 on Week 0


title: EBF_ER_INP-Rep1

city: Hyderabad

first: Jagan

last: Pongubala

state: Telangana

address: Gachibowli

department: Animal Biology

country: India

institute: University of Hyderabad

data_processing:
Raw reads were aligned to the GRCh38/mm10 genome assembly.
Alignment was done using Bowtie (version 1.1.2) allowing 2 mismatches.
Peaks were called using MACS 1.4.3 (Zhang et al., 2008).
Genome_build: GRCh38/mm10
Supplementary_files_format_and_content: peaks

source_name: Early-B cells

growth_protocol: Early-B cells were obtained by in vitro differentiation of Ebf1-/- progenitors by expressing transcription factor EBF1 (via MigR1-EBF1.ERconstruct), followed by culturing on OP9 stromal cells in presence of cytokines SCF, FLT3-L, IL-7,  and 4-O-Hydroxy-tamoxifen for two days.

extract_protocol:
INPUT (genomic DNA) or IP-DNA was isolated using ChIP DNA clean & concentrator columns (Zymo Research) and subsequently used for library preparation.
The libraries for INPUT (genomic DNA) and IP-DNA samples were prepared using NEBNext Ultra II DNA Library prep kit (NEB) as per manufacturer's instructions.

treatment_protocol: Cells were fixed in OptiMEM containing 1% formaldehyde and formaldehyde was quenched with 0.2 M glycine for 10min. Nuclei were lysed and precleared sonicated chromatin was incubated with Anti-H3K4me3 antibody and the immunoprecipitated DNA was isolated. Genomic DNA was used as INPUT sample.

value: In vitro differentiated cells

tag: antibody


title: Whole blood, SLE Patient 107 Follow-up on Week 36; IFN-K

description:
AP539036A29
A2786_2505

source_name: SLE Patient 107 Follow-up on Week 36

value: SLE

value: Patient 107


title: Whole blood, SLE patient 35 Follow-up on Week 36, placebo

description:
AP386677A07
A2786_2224

source_name: SLE Patient 35 Follow-up on Week 36

value: Patient 35


title: EBF-NULL_INP_Rep2

source_name: Ebf1-/- Progenitors

value: Progenitor cells


title: Whole blood, SLE Patient 94 Dose 1 on Week 0; IFN-K

description:
AI667573-7
A2786_2567

source_name: SLE Patient 94 Dose 1 on Week 0

value: Patient 94


title: EBF-ER_H3k4me3_Rep2

value: Anti-H3K4me3 (Abcam, ab8580)


title: EBF_ER_INP-Rep2


title: EBF-NULL_INP_Rep1


title: EBF-ER_H3k4me3_Rep1


title: EBF-NULL_H3k4me3_Rep2


title: Whole blood, SLE Patient 114 Dose 1 on Week 0; IFN-K

description:
AI365536-7
A2786_2221

source_name: SLE Patient 114 Dose 1 on Week 0

value: IFN-K

value: Blood


title: Whole blood, SLE patient 37 Dose 1 on Week 0, placebo

description:
AI750720-29
A2786_2218

source_name: SLE Patient 37 Dose 1 on Week 0

value: Patient 37


title: EBF-NULL_H3k4me3_Rep1


title: Whole blood, SLE patient 2 Dose 1 on Week 0, placebo

description:
AI622645-7
A2786_2220

source_name: SLE Patient 2 Dose 1 on Week 0

value: Patient 2


title: Whole blood, SLE patient 29 Dose 1 on Week 0, placebo

description:
AI365519-29
A2786_2593

source_name: SLE Patient 29 Dose 1 on Week 0

value: Patient 29


title: Whole blood, SLE Patient 107 Dose 1 on Week 0; IFN-K

description:
AI363654-7
A2786_2217

source_name: SLE Patient 107 Dose 1 on Week 0


title: Day3_10nM

city: Tokyo

first: Hayato

last: Takahashi

address: 35 Shinanomachi Shinjuku-ku

department: Dermatology

country: Japan

institute: Keio University School of Medicine

data_processing:
The DNA libraries were sequenced using HiSeq 2500 (Illumina). The DNA sequence was trimmed using the trim galore program (version 0.4.4; http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with the cutadapt program (version 1.14), and the trimmed sequence was mapped to the mouse genome (mm9) using STAR (version 020201). The number of reads of each gene was calculated using featureCounts (version 1.6.2) with the mm9 annotation [version July 17, 2015 (UCSC)].
Genome_build: mm9
Supplementary_files_format_and_content: Excel file with read count

source_name: CD4+ T cells

extract_protocol:
Total RNA was isolated using the RNeasy Mini Kit (Qiagen), according to the manufacturer’s instructions.
The quality of extracted RNA was evaluated using the RNA integrity number and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The DNA libraries for mRNA-seq were constructed using the SureSelect Strand-Specific RNA Library Prep Kit (Agilent Technologies), according to the manufacturer’s instructions.

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 10 nM 25OHC. 3 days later, cells were collected for analysis.


title: Day3_100nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 100 nM 25OHC. 3 days later, cells were collected for analysis.


title: Day3_1000nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 1000 nM 25OHC. 3 days later, cells were collected for analysis.


title: Whole blood, SLE patient 35 Dose 4 on Week 12, placebo

description:
AI782204-7
A2786_2216

source_name: SLE Patient 35 Dose 4 on Week 12

value: PBO

value: Dose 4 on Week 12


title: Whole blood, SLE patient 31 Dose 1 on Week 0, placebo

description:
AI702650-29
A2786_2605

source_name: SLE Patient 31 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 31


title: Whole blood, SLE Patient 117 Dose 1 on Week 0; IFN-K

description:
AI570847-29
A2786_2607

source_name: SLE Patient 117 Dose 1 on Week 0

value: SLE

value: Patient 117


title: Day2_100nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 100 nM 25OHC. 2 days later, cells were collected for analysis.


title: Whole blood, SLE patient 3 Dose 4 on Week 12, placebo

description:
AI622752-28
A2786_2213

source_name: SLE Patient 3 Dose 4 on Week 12

value: Patient 3


title: Whole blood, SLE Patient 94 Dose 4 on Week 12; IFN-K

description:
AP157005A28
A2786_2211

source_name: SLE Patient 94 Dose 4 on Week 12

value: Patient 94


title: Whole blood, SLE Patient 114 Dose 4 on Week 12; IFN-K

description:
AI706776-7
A2786_2212

source_name: SLE Patient 114 Dose 4 on Week 12

value: IFN-K

value: Patient 114


title: Day2_0nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with nM 25OHC. 2 days later, cells were collected for analysis.


title: Day2_10nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 10 nM 25OHC. 2 days later, cells were collected for analysis.


title: Day3_0nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with nM 25OHC. 3 days later, cells were collected for analysis.


title: Day1_1000nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 1000 nM 25OHC. 1 day later, cells were collected for analysis.


title: Day2_1000nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 1000 nM 25OHC. 2 days later, cells were collected for analysis.


title: Day1_0nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with nM 25OHC. 1 day later, cells were collected for analysis.


title: Whole blood, SLE patient 35 Dose 1 on Week 0, placebo

description:
AI576238-7
A2786_2206

source_name: SLE Patient 35 Dose 1 on Week 0

value: PBO

value: Blood

value: Patient 35


title: Whole blood, SLE patient 29 Dose 4 on Week 12, placebo

description:
AI719712-28
A2786_2209

source_name: SLE Patient 29 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 29


title: Whole blood, SLE Patient 117 Dose 4 on Week 12; IFN-K

description:
AP119140A28
A2786_2608

source_name: SLE Patient 117 Dose 4 on Week 12

value: SLE

value: Patient 117


title: Whole blood, SLE Patient 125 Dose 1 on Week 0; IFN-K

description:
AI571906-29
A2786_2207

source_name: SLE Patient 125 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 125


title: Whole blood, SLE patient 2 Dose 4 on Week 12, placebo

description:
AP118194A33
A2786_2541

source_name: SLE Patient 2 Dose 4 on Week 12

value: Patient 2


title: Whole blood, SLE Patient 125 Dose 4 on Week 12; IFN-K

description:
AI750732-7
A2786_2610

source_name: SLE Patient 125 Dose 4 on Week 12

value: IFN-K


title: Day1_10nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 10 nM 25OHC. 1 day later, cells were collected for analysis.


title: Day1_100nM

value: Naive CD4+ T cells (CD4+CD62LhiCD44loCD25- cells) were cultured in plate-bound anti-CD3 and anti-CD28 (10 ug/ml each) in combination with 100 nM 25OHC. 1 day later, cells were collected for analysis.


title: Whole blood, SLE patient 31 Dose 4 on Week 12, placebo

description:
AI690574-8
A2786_2201

source_name: SLE Patient 31 Dose 4 on Week 12

value: Patient 31


title: Whole blood, SLE patient 29 Dose 5 on Week 24, placebo

description:
AI719709-7
A2786_2594

source_name: SLE Patient 29 Dose 5 on Week 24

value: Dose 5 on Week 24


title: Whole blood, SLE Patient 112 Dose 1 on Week 0; IFN-K

description:
AI365582-7
A2786_2203

source_name: SLE Patient 112 Dose 1 on Week 0

value: Patient 112


title: Whole blood, SLE patient 37 Dose 4 on Week 12, placebo

description:
AI750733-7
A2786_2204

source_name: SLE Patient 37 Dose 4 on Week 12

value: Patient 37


title: Whole blood, SLE Patient 112 Dose 4 on Week 12; IFN-K

description:
AP118383A28
A2786_2592

source_name: SLE Patient 112 Dose 4 on Week 12


title: Whole blood, SLE Patient 114 Dose 5 on Week 24; IFN-K

description:
AP250466A07
A2786_2198

source_name: SLE Patient 114 Dose 5 on Week 24

value: Patient 114


title: Whole blood, SLE patient 3 Dose 5 on Week 24, placebo

description:
AP417227A29
A2786_2542

source_name: SLE Patient 3 Dose 5 on Week 24

value: PBO

value: Blood

value: Patient 3


title: Whole blood, SLE patient 2 Dose 5 on Week 24, placebo

description:
AP110704A08
A2786_2194

source_name: SLE Patient 2 Dose 5 on Week 24


title: Whole blood, SLE Patient 107 Dose 4 on Week 12; IFN-K

description:
AI720445-28
A2786_2590

source_name: SLE Patient 107 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 107


title: Whole blood, SLE Patient 125 Dose 5 on Week 24; IFN-K

description:
AI750731-7
A2786_2196

source_name: SLE Patient 125 Dose 5 on Week 24

value: SLE


title: Whole blood, SLE patient 31 Dose 5 on Week 24, placebo

description:
AP133143A28
A2786_2606

source_name: SLE Patient 31 Dose 5 on Week 24


title: Whole blood, SLE patient 62 Dose 5 on Week 24, placebo

description:
EP050833A08
A2786_2188rr

source_name: SLE Patient 62 Dose 5 on Week 24

value: Patient 62


title: Whole blood, SLE patient 15 Follow-up on Week 36, placebo

description:
EF035544-8
A2786_2192

source_name: SLE Patient 15 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 15


title: Whole blood, SLE patient 62 Dose 1 on Week 0, placebo

description:
EE892717-38
A2786_2653

source_name: SLE Patient 62 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 151 Dose 5 on Week 24 ; IFN-K

description:
EP135361A08
A2786_2189

source_name: SLE Patient 151 Dose 5 on Week 24

value: IFN-K

value: Patient 151


title: AGO2RIP_EARLY_T_Replicate2

description:
IP RNA
Processed_file_Ago2RIP_counts.xlsx

data_processing:
The miRNA reads were aligned to the miRNA database (miRbase V22)  using bowtie1.2.2.
Reads mapping to mouse miRNAs with a maximum of two mismatches were further used to identify differentially expressed miRNAs between samples.
For Ago2-RIP, the raw reads obtained after sequencing were filtered for quality and aligned to mouse transcriptome (mm10) using Tophat (V2).
Read quantification was performed using htseq-count with UCSC RefSeq gene annotation.
DESeq2 was used to identify the differentially expressed genes.
Genome_build: mm10
Supplementary_files_format_and_content: Excel file with normalized counts for each miRNA and every sample
Supplementary_files_format_and_content: Excel file with normalized gene counts for every gene and every sample

source_name: Early-T cells

growth_protocol: Early-B cells were obtained by in vitro differentiation of Ebf1-/- progenitors by expressing TF EBF1 (via MigR1-EBF1.ER vector), followed by culturing on OP9 stromal cells in presence of cytokines SCF, FLT3-L, IL-7  and 4-O-Hydroxy-tamoxifen. Early-T cells were obtained by culturing Ebf1-/- progenitors on OP9-DL1 stroma for 5 days in presence of cytokines SCF, FLT3-L and IL-7.

extract_protocol:
Total RNA(INPUT) or IP-RNA was isolated using Trizol reagent and subsequently used for library preparation.
miRNA libraries were prepared using TrueSeq small RNA library preparation kit (Illumina) as per manufacturer's instructions. The libraries for INPUT and AGO2-RIP RNA samples were prepared using NEBNext Ultra II Directional RNA Library Prep kit (NEB) as per manufacturer's instructions.
miRNA-seq, RNA-seq, Other (RIP-seq)

treatment_protocol: For Ago2-RIP, pre-cleared cell lysates were incubated with Anti-Ago2 antibody and the immunoprecipitated RNA was isolated. Total RNA obtained from cell lysate was used as INPUT sample.

value: In vitro differentiated cells

value: Anti-Ago2 (Abcam, ab32381)


title: AGO2RIP_EARLY_B_Replicate1

source_name: Early-B cells


title: Whole blood, SLE Patient 150 Dose 4 on Week 12 ; IFN-K

description:
EF173552-29
A2786_2187

source_name: SLE Patient 150 Dose 4 on Week 12

value: Patient 150


title: AGO2RIP_EARLY_T_Replicate1


title: AGO2RIP_EBFNULL_Replicate1

source_name: Ebf1-/- Progenitors

value: Progenitor cells


title: Whole blood, SLE Patient 148 Dose 5 on Week 24 ; IFN-K

description:
EF085373-8
A2786_2183

source_name: SLE Patient 148 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 148


title: AGO2RIP_EBFNULL_Replicate2


title: Whole blood, SLE patient 35 Dose 5 on Week 24, placebo

description:
AI782208-7
A2786_2195

source_name: SLE Patient 35 Dose 5 on Week 24

value: PBO

value: Blood

value: Patient 35


title: Whole blood, SLE Patient 150 Dose 1 on Week 0; IFN-K

description:
EE806978-7
A2786_2185

source_name: SLE Patient 150 Dose 1 on Week 0


title: Whole blood, SLE Patient 151 Dose 1 on Week 0; IFN-K

description:
EE806979-29
A2786_2182

source_name: SLE Patient 151 Dose 1 on Week 0


title: Whole blood, SLE patient 59 Dose 5 on Week 24, placebo

description:
EP141110A08
A2786_2256

source_name: SLE Patient 59 Dose 5 on Week 24

value: Patient 59


title: Whole blood, SLE Patient 153 Follow-up on Week 36 ; IFN-K

description:
EF196227-8
A2786_2191

source_name: SLE Patient 153 Follow-up on Week 36

value: SLE

value: Patient 153


title: AGO2RIP_EARLY_B_Replicate2


title: Whole blood, SLE Patient 150 Follow-up on Week 36 ; IFN-K

description:
EP135365A30
A2786_2190

source_name: SLE Patient 150 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE Patient 148 Dose 1 on Week 0; IFN-K

description:
EF004590-29
A2786_2180

source_name: SLE Patient 148 Dose 1 on Week 0


title: Whole blood, SLE Patient 141 Follow-up on Week 36 ; IFN-K

description:
EP129877A30
A2786_2181

source_name: SLE Patient 141 Follow-up on Week 36

value: Patient 141


title: Whole blood, SLE Patient 141 Dose 5 on Week 24 ; IFN-K

description:
EF347925-8
A2786_2176

source_name: SLE Patient 141 Dose 5 on Week 24


title: INPUT_EARLY_B_Replicate1

description:
Total RNA
Processed_file_Ago2RIP_counts.xlsx


title: Whole blood, SLE Patient 137 Dose 5 on Week 24 ; IFN-K

description:
EP170896A29
A2786_2184

source_name: SLE Patient 137 Dose 5 on Week 24

value: Patient 137


title: Whole blood, SLE patient 63 Dose 1 on Week 0, placebo

description:
EE891519-29
A2786_2178

source_name: SLE Patient 63 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 63


title: INPUT_EBFNULL_Replicate1


title: INPUT_EARLY_T_Replicate1

value: In vitro differentiated cells


title: miRNA_EarlyT_cell_Replicate2

description:
microRNA
Processed_file_miRNA_counts.xlsx


title: Whole blood, SLE Patient 141 Dose 4 on Week 12 ; IFN-K

description:
EF086405-8
A2786_2177

source_name: SLE Patient 141 Dose 4 on Week 12

value: IFN-K

value: Dose 4 on Week 12


title: INPUT_EARLY_B_Replicate2


title: miRNA_EarlyB_cell_Replicate1


title: Whole blood, SLE patient 15 Dose 5 on Week 24, placebo

description:
EP082069A08
A2786_2171

source_name: SLE Patient 15 Dose 5 on Week 24

value: Patient 15


title: Whole blood, SLE Patient 153 Dose 1 on Week 0; IFN-K

description:
EE814519-7
A2786_2632

source_name: SLE Patient 153 Dose 1 on Week 0


title: miRNA_Ebfnull_Replicate1

value: Progenitor cells


title: INPUT_EBFNULL_Replicate2


title: Whole blood, SLE patient 17 Dose 5 on Week 24, placebo

description:
EF249165-29
A2786_2179

source_name: SLE Patient 17 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 17


title: Whole blood, SLE patient 20 Dose 5 on Week 24, placebo

description:
EF216840-29
A2786_2589

source_name: SLE Patient 20 Dose 5 on Week 24

value: PBO

value: Blood

value: Patient 20


title: Whole blood, SLE Patient 153 Dose 5 on Week 24 ; IFN-K

description:
EF196221-29
A2786_2633

source_name: SLE Patient 153 Dose 5 on Week 24

value: SLE


title: Whole blood, SLE patient 17 Dose 4 on Week 12, placebo

description:
EF249167-8
A2786_2167

source_name: SLE Patient 17 Dose 4 on Week 12


title: Whole blood, SLE patient 20 Dose 1 on Week 0, placebo

description:
EE602198-7
A2786_2166

source_name: SLE Patient 20 Dose 1 on Week 0


title: Blastocyst cultured for 0 hours after warming [59]

city: Valencia

first: Mª José

last: de los Santos Molina

address: C/ Plaça de la Policia Local, 3

country: Spain

institute: IVIRMA Valencia

data_processing:
Pseudo-aligment and quantification were made with Salmon algorithm v1.2.1
Correlation analysis, principal component study and differential expression analysis were performed with DESeq2 package v1.24.0. Differential gene expression analyses were done using the parametric Wald test, with Benjamini-Hochberg adjustment (padj). Genes with padj <0.01 and a log2 fold change of ±2 were considered significantly expressed genes (DEGs).
fgsea package v1.10.1 was used for gene set enrichment of KEGG pathways and GO terms (Cellular Component - Biological Processes - Molecular Function)
Genome_build: GRCh38
Supplementary_files_format_and_content: tab-delimited text files that include TPM values and raw counts per transcript

source_name: Blastocyst

extract_protocol:
SMART-Seq v4 Ultra-Low Input RNA kit for Sequencing (Takara Bio, USA) and AMPure XP magnetic beads (Illumina, CA, USA)
NexteraXT DNA sample preparation (Illumina, CA, USA)

treatment_protocol: The specimens were warmed and they were immediately collected for RNA extraction, except for the group of "blastocysts cultured for 4-5 hours after warming" which were collected after 4-5 hours of culture after warming.

tag: biotype

value: Blastocyst

tag: culture time after warming (hours)


title: Whole blood, SLE Patient 153 Dose 4 on Week 12 ; IFN-K

description:
EF077711-29
A2786_2174

source_name: SLE Patient 153 Dose 4 on Week 12

value: Patient 153


title: Whole blood, SLE patient 63 Dose 4 on Week 12, placebo

description:
EF229724-8
A2786_2164

source_name: SLE Patient 63 Dose 4 on Week 12


title: Blastocyst cultured for 0 hours after warming [60]


title: Non-arrested cleavage-stage embryo [58]

source_name: Embryo

value: Non-arrested cleavage-stage embryo


title: Non-arrested cleavage-stage embryo [56]


title: miRNA_Ebfnull_Replicate2

source_name: Ebf1-/- Progenitors


title: Whole blood, SLE Patient 141 Dose 1 on Week 0; IFN-K

description:
EF039914-7
A2786_2175

source_name: SLE Patient 141 Dose 1 on Week 0

value: Patient 141


title: miRNA_EarlyB_cell_Replicate2

source_name: Early-B cells


title: Blastocyst cultured for 4-5 hours after warming [48]


title: Whole blood, SLE patient 15 Dose 4 on Week 12, placebo

description:
EF035542-29
A2786_2569

source_name: SLE Patient 15 Dose 4 on Week 12


title: miRNA_EarlyT_cell_Replicate1

source_name: Early-T cells


title: Non-arrested cleavage-stage embryo [44]


title: INPUT_EARLY_T_Replicate2


title: Non-arrested cleavage-stage embryo [57]


title: Arrested cleavage-stage embryo [54]

value: Arrested cleavage-stage embryo


title: Whole blood, SLE patient 17 Dose 1 on Week 0, placebo

description:
EE722484-7
A2786_2156

source_name: SLE Patient 17 Dose 1 on Week 0

value: Dose 1 on Week 0


title: MII oocyte [52]

source_name: Oocyte

value: MII oocyte


title: Whole blood, SLE Patient 137 Dose 4 on Week 12 ; IFN-K

description:
EF342026-8
A2786_2157

source_name: SLE Patient 137 Dose 4 on Week 12

value: IFN-K

value: Patient 137


title: Whole blood, SLE patient 62 Follow-up on Week 36, placebo

description:
EP293651A08
A2786_2155rr

source_name: SLE Patient 62 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 62


title: Whole blood, SLE Patient 137 Dose 1 on Week 0; IFN-K

description:
EE744637-7
A2786_2173

source_name: SLE Patient 137 Dose 1 on Week 0


title: Whole blood, SLE patient 63 Dose 5 on Week 24, placebo

description:
EF229725-29
A2786_2161

source_name: SLE Patient 63 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 63


title: MII oocyte [39]


title: Whole blood, SLE patient 20 Follow-up on Week 36, placebo

description:
EP211798A08
A2786_2151rr

source_name: SLE Patient 20 Follow-up on Week 36

value: PBO


title: Blastocyst cultured for 4-5 hours after warming (high Mitoscore®) [37]

tag: mitoscore® level

value: High


title: Whole blood, SLE Patient 148 Follow-up on Week 36 ; IFN-K

description:
EP130302A08
A2786_2150

source_name: SLE Patient 148 Follow-up on Week 36

value: Blood

value: Patient 148


title: Whole blood, SLE patient 17 Follow-up on Week 36, placebo

description:
EP116581A03
A2786_2154

source_name: SLE Patient 17 Follow-up on Week 36

value: SLE

value: Patient 17


title: Whole blood, SLE Patient 148 Dose 4 on Week 12 ; IFN-K

description:
EF085372-29
A2786_2163rr

source_name: SLE Patient 148 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Whole blood, SLE Patient 151 Dose 4 on Week 12; IFN-K

description:
EE806994-8
A2786_2168

source_name: SLE Patient 151 Dose 4 on Week 12

value: Patient 151


title: Blastocyst cultured for 4-5 hours after warming (high Mitoscore®) [49]

source_name: Blastocyst

value: Blastocyst


title: Non-arrested cleavage-stage embryo [45]

source_name: Embryo

value: Non-arrested cleavage-stage embryo


title: Whole blood, SLE patient 15 Dose 1 on Week 0, placebo

description:
EE845290-7
A2786_2165

source_name: SLE Patient 15 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 15


title: MII oocyte [40]

value: MII oocyte


title: Whole blood, SLE patient 63 Follow-up on Week 36, placebo

description:
EF229734-9
A2786_2149

source_name: SLE Patient 63 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE patient 47 Follow-up on Week 36, placebo

description:
SP146675A08
A2786_2148

source_name: SLE Patient 47 Follow-up on Week 36

value: Patient 47


title: Whole blood, SLE patient 62 Dose 4 on Week 12, placebo

description:
EP050832A08
A2786_2162

source_name: SLE Patient 62 Dose 4 on Week 12

value: Patient 62


title: Whole blood, SLE Patient 150 Dose 5 on Week 24; IFN-K

description:
EF173562-33
A2786_2160

source_name: SLE Patient 150 Dose 5 on Week 24

value: IFN-K

value: Dose 5 on Week 24

value: Patient 150


title: MII oocyte [38]

source_name: Oocyte


title: Blastocyst cultured for 0 hours after warming (low Mitoscore®) [35]

value: Low


title: Arrested cleavage-stage embryo [31]

value: Arrested cleavage-stage embryo


title: Arrested cleavage-stage embryo [53]


title: MII oocyte [27]


title: MII oocyte [26]


title: Non-arrested cleavage-stage embryo [33]


title: Blastocyst cultured for 0 hours after warming [34]


title: Blastocyst cultured for 4-5 hours after warming [36]


title: Arrested cleavage-stage embryo [30]


title: Blastocyst cultured for 4-5 hours after warming [25]


title: Blastocyst cultured for 0 hours after warming (low Mitoscore®) [22]


title: Blastocyst cultured for 0 hours after warming (high Mitoscore®) [23]

value: High


title: Non-arrested cleavage-stage embryo [20]


title: Blastocyst cultured for 4-5 hours after warming [24]


title: Non-arrested cleavage-stage embryo [21]


title: Arrested cleavage-stage embryo [18]


title: MII oocyte [13]


title: Whole blood, SLE Patient 151 Follow-up on Week 36 ; IFN-K

description:
EP135366A30
A2786_2153rr

source_name: SLE Patient 151 Follow-up on Week 36

value: SLE

value: Blood


title: MII oocyte [14]


title: MII oocyte [17]


title: MII oocyte [15]


title: Blastocyst cultured for 4-5 hours after warming (low Mitoscore®) [12]


title: Whole blood, SLE Patient 137 Follow-up on Week 36; IFN-K

description:
EE744643-7
A2786_2152

source_name: SLE Patient 137 Follow-up on Week 36

value: Patient 137


title: Whole blood, SLE patient 47 Dose 5 on Week 24, placebo

description:
S5634544-7
A2786_2144

source_name: SLE Patient 47 Dose 5 on Week 24

value: PBO


title: Blastocyst cultured for 4-5 hours after warming [11]

value: Blastocyst


title: Whole blood, SLE patient 20 Dose 4 on Week 12, placebo

description:
EF216839-29
A2786_2570

source_name: SLE Patient 20 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 20


title: Whole blood, SLE patient 42 Dose 5 on Week 24, placebo

description:
S5634025-7
A2786_2143

source_name: SLE Patient 42 Dose 5 on Week 24

value: Patient 42


title: Whole blood, SLE Patient 131 Dose 4 on Week 12; IFN-K

description:
S5634552-28
A2786_2137

source_name: SLE Patient 131 Dose 4 on Week 12

value: Patient 131


title: Whole blood, SLE patient 42 Follow-up on Week 36, placebo

description:
SP107519A07
A2786_2147

source_name: SLE Patient 42 Follow-up on Week 36

value: Follow-up on Week 36


title: Whole blood, SLE patient 47 Dose 4 on Week 12, placebo

description:
S5634545-28
A2786_2140

source_name: SLE Patient 47 Dose 4 on Week 12

value: Patient 47


title: Whole blood, SLE patient 42 Dose 1 on Week 0, placebo

description:
S5461143-29
A2786_2135

source_name: SLE Patient 42 Dose 1 on Week 0

value: Dose 1 on Week 0


title: Whole blood, SLE Patient 93 Dose 5 on Week 24; IFN-K

description:
AI715905-7
A2786_2133

source_name: SLE Patient 93 Dose 5 on Week 24

value: IFN-K

value: Dose 5 on Week 24

value: Patient 93


title: Whole blood, SLE patient 45 Dose 4 on Week 12, placebo

description:
S5461121-7
A2786_2136

source_name: SLE Patient 45 Dose 4 on Week 12

value: Patient 45


title: Blastocyst cultured for 0 hours after warming [10]

source_name: Blastocyst


title: Whole blood, SLE Patient 131 Dose 5 on Week 24; IFN-K

description:
S5634546-7
A2786_2142

source_name: SLE Patient 131 Dose 5 on Week 24


title: Whole blood, SLE patient 47 Dose 1 on Week 0, placebo

description:
S5461095-29
A2786_2138

source_name: SLE Patient 47 Dose 1 on Week 0


title: Whole blood, SLE patient 42 Dose 4 on Week 12, placebo

description:
S5634029-7
A2786_2139

source_name: SLE Patient 42 Dose 4 on Week 12


title: Whole blood, SLE Patient 131 Follow-up on Week 36; IFN-K

description:
SP107442A07
A2786_2146rr

source_name: SLE Patient 131 Follow-up on Week 36


title: Whole blood, SLE Patient 110 Dose 5 on Week 24; IFN-K

description:
AP118407A08
A2786_2127

source_name: SLE Patient 110 Dose 5 on Week 24

value: Patient 110


title: Whole blood, SLE patient 45 Dose 5 on Week 24, placebo

description:
S5634075-7
A2786_2141

source_name: SLE Patient 45 Dose 5 on Week 24

value: SLE


title: Whole blood, SLE Patient 92 Dose 5 on Week 24; IFN-K

description:
AP212852A07
A2786_2129

source_name: SLE Patient 92 Dose 5 on Week 24

value: Blood

value: Patient 92


title: Whole blood, SLE Patient 131 Dose 1 on Week 0; IFN-K

description:
S5461096-29
A2786_2134

source_name: SLE Patient 131 Dose 1 on Week 0


title: Whole blood, SLE patient 45 Follow-up on Week 36, placebo

description:
S5634105-7
A2786_2145

source_name: SLE Patient 45 Follow-up on Week 36

value: PBO


title: Whole blood, SLE patient 5 Follow-up on Week 36, placebo

description:
AP417260A07
A2786_2132

source_name: SLE Patient 5 Follow-up on Week 36

value: Patient 5


title: Blastocyst cultured for 0 hours after warming [9]

value: Blastocyst


title: MII oocyte [8]

source_name: Oocyte

value: MII oocyte


title: Whole blood, SLE patient 6 Dose 5 on Week 24, placebo

description:
AP143615A07
A2786_2128

source_name: SLE Patient 6 Dose 5 on Week 24

value: Patient 6


title: Non-arrested cleavage-stage embryo [4]

source_name: Embryo

value: Non-arrested cleavage-stage embryo


title: Whole blood, SLE patient 11 Dose 5 on Week 24, placebo

description:
AI715908-7
A2786_2131

source_name: SLE Patient 11 Dose 5 on Week 24

value: Patient 11


title: Whole blood, SLE Patient 111 Dose 5 on Week 24; IFN-K

description:
AP118406A08
A2786_2130

source_name: SLE Patient 111 Dose 5 on Week 24

value: Patient 111


title: Non-arrested cleavage-stage embryo [3]


title: Blastocyst cultured for 4-5 hours after warming [1]


title: Blastocyst cultured for 4-5 hours after warming [2]


title: Whole blood, SLE patient 30 Dose 5 on Week 24, placebo

description:
AP133144A07
A2786_2126

source_name: SLE Patient 30 Dose 5 on Week 24

value: Patient 30


title: Whole blood, SLE Patient 93 Dose 4 on Week 12; IFN-K

description:
AP157004A07
A2786_2124

source_name: SLE Patient 93 Dose 4 on Week 12

value: IFN-K

value: Dose 4 on Week 12


title: Microglia gp120 p38α KO 424

city: Riverside

first: Marcus

last: Kaul

state: California

address: 900 University Ave, SOM RB Room 311

department: Biomedical Sciences

institute: University of California, Riverside

data_processing:
Illumina BCL2FASTQ software used for base calling and demultiplexing.
Sequenced reads were trimmed for adaptor sequence, and masked for low-complexity or low-quality sequence using fastp (QC>30), mapped to mm10 (mouse) whole genome using Expression count (STAR) in Basepairtech software.
Using Expression count (STAR) in Basepairtech software, sequences were aligned, number of reads falling in the exons, introns and intergenic region were counted and Reads Per Kilobase of exon per Megabase of library size (RPKM) and TPM (Transcripts Per Million) were calculated.
Gene expression analysis was done using Differential expression (DESeq2) pipeline in Basepairtech software.
Genome_build: mm10
Supplementary_files_format_and_content: FPKM and TPM values for each Sample by transcript and gene.
Supplementary_files_format_and_content: diffentially expressed genes compared between 2 genptypes representing fold change, p-values and adjusted p-values.

source_name: Microglia gp120 p38α KO

extract_protocol:
Brains of mice perfused with 0.9% Saline  under terminal anesthesia were removed and microglial cells were harvested from a single-cell suspension of whole brain using a published percoll gradient method. Cells at the percoll interface were collected, stained using CD11b and CD45 antibodies and sorted uing flow cytometry. RNA was extracted from sorted microglia (CD11b+, CD45intermediate) using Allprep DNA/RNA/miRNA Universal kit (Qiagen, Cat no. 80224).
QIAseq FX single cell RNA library kit (Qiagen, Cat no. 180733) was used for the construction of sequencing libraries. Quality of RNA and cDNA libraries was determined using bioanalyzer.

tag: strain background

value: Brain

tag: age

value: 1 year

tag: genotype

value: gp120 p38alpha KO (p38F/F Cre+/- gp120+)

tag: Sex

value: Female

value: Microglia


title: Microglia gp120 p38α KO 434


title: Microglia p38α KO 498

source_name: Microglia p38α KO

value: p38alpha KO (p38F/F Cre+/- gp120-)


title: Whole blood, SLE patient 30 Dose 4 on Week 12, placebo

description:
AI755303-33
A2786_2121

source_name: SLE Patient 30 Dose 4 on Week 12

value: SLE

value: PBO

value: Blood


title: Microglia p38α KO 195

value: Male


title: Microglia gp120 p38α KO 390


title: Whole blood, SLE patient 5 Dose 5 on Week 24, placebo

description:
AI698594-7
A2786_2123

source_name: SLE Patient 5 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Patient 5


title: Microglia gp120 p38α KO 502


title: Microglia p38α KO 533


title: Microglia gp120 p38α KO 504


title: Microglia p38α KO 385


title: Microglia gp120 p38α KO 481


title: Microglia p38α KO 578


title: Whole blood, SLE Patient 92 Dose 4 on Week 12; IFN-K

description:
AI715914-28
A2786_2120

source_name: SLE Patient 92 Dose 4 on Week 12

value: Patient 92


title: Whole blood, SLE patient 11 Dose 4 on Week 12, placebo

description:
AP157007A28
A2786_2119

source_name: SLE Patient 11 Dose 4 on Week 12

value: Patient 11


title: Whole blood, SLE patient 5 Dose 4 on Week 12, placebo

description:
AI698598-7
A2786_2116

source_name: SLE Patient 5 Dose 4 on Week 12


title: Whole blood, SLE Patient 111 Dose 4 on Week 12; IFN-K

description:
AP118382A28
A2786_2118

source_name: SLE Patient 111 Dose 4 on Week 12

value: Patient 111


title: Microglia p38α KO 500


title: Whole blood, SLE Patient 111 Dose 1 on Week 0; IFN-K

description:
AI553015-7
A2786_2115

source_name: SLE Patient 111 Dose 1 on Week 0

value: IFN-K

value: Dose 1 on Week 0


title: Microglia gp120 372

source_name: Microglia gp120

value: Brain


title: Microglia gp120 341

value: 1 year


title: Whole blood, SLE Patient 90 Dose 4 on Week 12; IFN-K

description:
AI698597-28
A2786_2543

source_name: SLE Patient 90 Dose 4 on Week 12

value: Dose 4 on Week 12

value: Patient 90


title: Microglia gp120 394

value: Microglia


title: Microglia gp120 465


title: Microglia WT 299

source_name: Microglia WT

value: wild type (p38F/F Cre-/- gp120-)

value: Female


title: Whole blood, SLE patient 11 Dose 1 on Week 0, placebo

description:
AI667572-29
A2786_2113

source_name: SLE Patient 11 Dose 1 on Week 0

value: SLE

value: PBO


title: Microglia WT 475


title: Microglia WT 476


title: Microglia gp120 507

value: Male


title: Whole blood, SLE Patient 90 Dose 5 on Week 24; IFN-K

description:
AI698596-7
A2786_2125

source_name: SLE Patient 90 Dose 5 on Week 24

value: Dose 5 on Week 24

value: Blood


title: Whole blood, SLE Patient 93 Dose 1 on Week 0; IFN-K

description:
AI667570-41
A2786_2565

source_name: SLE Patient 93 Dose 1 on Week 0

value: Patient 93


title: Whole blood, SLE patient 30 Dose 1 on Week 0, placebo

description:
AI365551-7
A2786_2110

source_name: SLE Patient 30 Dose 1 on Week 0

value: Patient 30


title: Whole blood, SLE patient 5 Dose 1 on Week 0, placebo

description:
AI142417-7
A2786_2109

source_name: SLE Patient 5 Dose 1 on Week 0

value: Patient 5


title: Whole blood, SLE patient 6 Follow-up on Week 36, placebo

description:
AP143622A07
A2786_2544

source_name: SLE Patient 6 Follow-up on Week 36

value: Follow-up on Week 36

value: Patient 6


title: Whole blood, SLE patient 6 Dose 4 on Week 12, placebo

description:
AI533198-7
A2786_2117

source_name: SLE Patient 6 Dose 4 on Week 12


title: Whole blood, SLE patient 11 Follow-up on Week 36, placebo

description:
AP157031A29
A2786_2547

source_name: SLE Patient 11 Follow-up on Week 36

value: Patient 11


title: Whole blood, SLE Patient 110 Follow-up on Week 36; IFN-K

description:
AP118397A29
A2786_2591

source_name: SLE Patient 110 Follow-up on Week 36

value: IFN-K

value: Patient 110


title: Microglia WT 354

value: Brain

value: 1 year


title: Whole blood, SLE Patient 92 Dose 1 on Week 0; IFN-K

description:
AI419448-29
A2786_2112

source_name: SLE Patient 92 Dose 1 on Week 0

value: Dose 1 on Week 0

value: Patient 92


title: Microglia gp120 373

value: Female

value: Microglia


title: Whole blood, SLE Patient 90 Dose 1 on Week 0; IFN-K

description:
AI539991-7
A2786_2111

source_name: SLE Patient 90 Dose 1 on Week 0

value: SLE

value: Patient 90


title: Whole blood, SLE patient 30 Follow-up on Week 36, placebo

description:
AP133159A29
A2786_2604

source_name: SLE Patient 30 Follow-up on Week 36

value: PBO

value: Blood


title: Whole blood, SLE Patient 92 Follow-up on Week 36; IFN-K

description:
AP157032A29
A2786_2546

source_name: SLE Patient 92 Follow-up on Week 36


title: Whole blood, SLE Patient 111 Follow-up on Week 36; IFN-K

description:
AP118395A07
A2786_2099

source_name: SLE Patient 111 Follow-up on Week 36

value: Patient 111


title: Whole blood, SLE Patient 110 Dose 1 on Week 0; IFN-K

description:
AI365583-29
A2786_2108

source_name: SLE Patient 110 Dose 1 on Week 0


title: Whole blood, SLE Patient 90 Follow-up on Week 36; IFN-K

description:
AP417259A07
A2786_2100

source_name: SLE Patient 90 Follow-up on Week 36


title: Whole blood, SLE Patient 93 Follow-up on Week 36 ; IFN-K

description:
AP157033A29
A2786_2566

source_name: SLE Patient 93 Follow-up on Week 36

value: Patient 93


title: Whole blood, SLE Patient 110 Dose 4 on Week 12; IFN-K

description:
AP118380A28
A2786_2098

source_name: SLE Patient 110 Dose 4 on Week 12

value: Dose 4 on Week 12


title: Microglia WT 353

source_name: Microglia WT

value: wild type (p38F/F Cre-/- gp120-)

value: Male


title: Microglia WT 281


title: Whole blood, SLE patient 6 Dose 1 on Week 0, placebo

description:
AI533178-7
A2786_2107

source_name: SLE Patient 6 Dose 1 on Week 0

value: Patient 6